Because B-Claim
stent I-Claim
placement I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
short-term I-Claim
outcomes I-Claim
, I-Claim
this B-Claim
treatment I-Claim
is I-Claim
preferable I-Claim
for I-Claim
patients I-Claim
expected I-Claim
to I-Claim
live I-Claim
less I-Claim
than I-Claim
2 I-Claim
months I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
spherical I-Claim
PVA I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
UAE I-Claim
. I-Claim

Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Nocturnal B-Claim
administration I-Claim
of I-Claim
BCAA I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

HRQOL B-Claim
evaluated I-Claim
3.2 I-Claim
to I-Claim
6.5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

Oral B-Claim
Etoposide I-Claim
therapy I-Claim
resulted I-Claim
in I-Claim
better I-Claim
total I-Claim
FLI-C I-Claim
QOL I-Claim
score I-Claim
than I-Claim
radiotherapy I-Claim
. I-Claim

Malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
MPE I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Bone B-Claim
metastases I-Claim
are I-Claim
a I-Claim
common I-Claim
cause I-Claim
of I-Claim
morbidity I-Claim
in I-Claim
patients I-Claim
with I-Claim
prostate I-Claim
carcinoma I-Claim
. I-Claim

Lower B-Claim
dosages I-Claim
of I-Claim
HRT I-Claim
were I-Claim
as I-Claim
effective I-Claim
as I-Claim
higher I-Claim
doses I-Claim
in I-Claim
improving I-Claim
climacteric I-Claim
symptoms I-Claim
and I-Claim
HRQOL I-Claim
ratings I-Claim
and I-Claim
had I-Claim
fewer I-Claim
safety I-Claim
concerns I-Claim
. I-Claim

Our B-Claim
present I-Claim
study I-Claim
shows I-Claim
that I-Claim
glutamine-enriched I-Claim
TPN I-Claim
may I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
the I-Claim
inflammatory I-Claim
status I-Claim
and I-Claim
decreasing I-Claim
the I-Claim
infectious I-Claim
morbidity I-Claim
in I-Claim
postoperative I-Claim
GI I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

Carboplatin/vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive-stage I-Claim
NSCLC I-Claim
. I-Claim

However B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim

The B-Claim
magnitude I-Claim
of I-Claim
improvement I-Claim
obtained I-Claim
was I-Claim
similar I-Claim
whether I-Claim
on I-Claim
a I-Claim
self-declared-healer- I-Claim
or I-Claim
an I-Claim
actor-provided I-Claim
" I-Claim
treatment I-Claim
" I-Claim
. I-Claim

Despite B-Claim
the I-Claim
early I-Claim
closure I-Claim
of I-Claim
the I-Claim
study I-Claim
and I-Claim
the I-Claim
lack I-Claim
of I-Claim
power I-Claim
of I-Claim
the I-Claim
comparison I-Claim
, I-Claim
it I-Claim
seems I-Claim
that I-Claim
ldLV5FU2 I-Claim
could I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
active I-Claim
, I-Claim
easier I-Claim
and I-Claim
less I-Claim
expensive I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
compared I-Claim
to I-Claim
classic I-Claim
LV5FU2 I-Claim
or I-Claim
weekly I-Claim
HD-FU I-Claim
. I-Claim

Chemotherapy B-Claim
provided I-Claim
on I-Claim
average I-Claim
an I-Claim
additional I-Claim
1.0 I-Claim
quality-adjusted I-Claim
life I-Claim
months I-Claim
within I-Claim
a I-Claim
restricted I-Claim
2-year I-Claim
time I-Claim
period I-Claim
from I-Claim
the I-Claim
time I-Claim
of I-Claim
resection I-Claim
. I-Claim

Despite B-Claim
its I-Claim
efficacy I-Claim
in I-Claim
reducing I-Claim
locoregional I-Claim
recurrence I-Claim
, I-Claim
EBRT I-Claim
should I-Claim
be I-Claim
avoided I-Claim
in I-Claim
patients I-Claim
with I-Claim
low- I-Claim
and I-Claim
intermediate-risk I-Claim
EC I-Claim
. I-Claim

Global B-Claim
health I-Claim
status/QOL I-Claim
substantially I-Claim
improved I-Claim
with I-Claim
ECF I-Claim
and I-Claim
remained I-Claim
similar I-Claim
to I-Claim
baseline I-Claim
with I-Claim
both I-Claim
docetaxel I-Claim
regimens I-Claim
. I-Claim

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

Radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side-effects I-Claim
. I-Claim

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
in I-Claim
women I-Claim
with I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
routinely I-Claim
used I-Claim
in I-Claim
some I-Claim
countries I-Claim
for I-Claim
staging I-Claim
the I-Claim
axilla I-Claim
despite I-Claim
limited I-Claim
data I-Claim
from I-Claim
randomized I-Claim
trials I-Claim
on I-Claim
morbidity I-Claim
and I-Claim
mortality I-Claim
outcomes I-Claim
. I-Claim

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

Unless B-Claim
additional I-Claim
follow-up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160-mg/d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

Intensive B-Claim
nutrition I-Claim
intervention I-Claim
following I-Claim
the I-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
results I-Claim
in I-Claim
improved I-Claim
dietary I-Claim
intake I-Claim
compared I-Claim
with I-Claim
standard I-Claim
practice I-Claim
and I-Claim
seems I-Claim
to I-Claim
beneficially I-Claim
impact I-Claim
nutrition-related I-Claim
outcomes I-Claim
previously I-Claim
observed I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

It B-Claim
is I-Claim
not I-Claim
known I-Claim
whether I-Claim
imatinib I-Claim
may I-Claim
be I-Claim
stopped I-Claim
in I-Claim
patients I-Claim
in I-Claim
whom I-Claim
disease I-Claim
is I-Claim
controlled I-Claim
. I-Claim

Low-dose B-Claim
CDDP I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

The B-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
for I-Claim
radiation I-Claim
oncology I-Claim
is I-Claim
a I-Claim
useful I-Claim
guide I-Claim
to I-Claim
the I-Claim
level I-Claim
of I-Claim
nutrition I-Claim
support I-Claim
required I-Claim
. I-Claim

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

In B-Claim
fatigued I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
nurse-led I-Claim
monitoring I-Claim
and I-Claim
protocolized I-Claim
treatment I-Claim
of I-Claim
physical I-Claim
symptoms I-Claim
is I-Claim
effective I-Claim
in I-Claim
alleviating I-Claim
fatigue I-Claim
. I-Claim

Improvements B-Claim
in I-Claim
total I-Claim
quality-of-life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

Vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
QoL I-Claim
. I-Claim

Morbidity B-Claim
associated I-Claim
with I-Claim
wound I-Claim
complications I-Claim
may I-Claim
translate I-Claim
into I-Claim
disability I-Claim
and I-Claim
quality-of-life I-Claim
disadvantages I-Claim
for I-Claim
patients I-Claim
treated I-Claim
with I-Claim
radiotherapy I-Claim
( I-Claim
RT I-Claim
) I-Claim
for I-Claim
soft I-Claim
tissue I-Claim
sarcoma I-Claim
( I-Claim
STS I-Claim
) I-Claim
of I-Claim
the I-Claim
extremities I-Claim
. I-Claim

The B-Claim
TAX I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel-platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
longer I-Claim
duration I-Claim
therapy I-Claim
( I-Claim
ACâ†’T I-Claim
) I-Claim
had I-Claim
greater I-Claim
symptom I-Claim
severity I-Claim
and I-Claim
poorer I-Claim
QOL I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
but I-Claim
did I-Claim
not I-Claim
differ I-Claim
from I-Claim
shorter I-Claim
duration I-Claim
treatments I-Claim
at I-Claim
12 I-Claim
months I-Claim
. I-Claim

Symptoms B-Claim
were I-Claim
common I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

Letrozole B-Claim
did I-Claim
not I-Claim
have I-Claim
an I-Claim
adverse I-Claim
impact I-Claim
on I-Claim
overall I-Claim
QOL I-Claim
. I-Claim

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

The B-Claim
survival I-Claim
with I-Claim
DOX I-Claim
and I-Claim
VNB I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
DOX I-Claim
alone I-Claim
in I-Claim
MBC I-Claim
. I-Claim

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

In B-Claim
the I-Claim
radical I-Claim
prostatectomy I-Claim
group I-Claim
, I-Claim
erectile I-Claim
dysfunction I-Claim
and I-Claim
urinary I-Claim
leakage I-Claim
were I-Claim
often I-Claim
consequences I-Claim
of I-Claim
surgery I-Claim
. I-Claim

The B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long-lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim

However B-Claim
, I-Claim
HRQoL I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end-of-treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs. I-Claim
MP I-Claim
. I-Claim

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim

Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

Newly B-Claim
available I-Claim
angiogenesis I-Claim
inhibitors I-Claim
should I-Claim
be I-Claim
preferred I-Claim
for I-Claim
these I-Claim
patients I-Claim
. I-Claim

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
CL I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

Vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
QOL I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
QOL I-Claim
perspective I-Claim
. I-Claim

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

HRQOL B-Claim
was I-Claim
better I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
treated I-Claim
with I-Claim
tamoxifen I-Claim
than I-Claim
those I-Claim
treated I-Claim
with I-Claim
exemestane I-Claim
or I-Claim
anastrozole I-Claim
. I-Claim

However B-Claim
, I-Claim
presuming I-Claim
these I-Claim
improvements I-Claim
were I-Claim
caused I-Claim
by I-Claim
the I-Claim
individualized I-Claim
homeopathic I-Claim
approach I-Claim
, I-Claim
the I-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
clearly I-Claim
that I-Claim
the I-Claim
specific I-Claim
effect I-Claim
of I-Claim
the I-Claim
remedy I-Claim
added I-Claim
further I-Claim
to I-Claim
the I-Claim
nonspecific I-Claim
effects I-Claim
of I-Claim
the I-Claim
consultation I-Claim
. I-Claim

CONNECT B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

This B-Claim
trial I-Claim
failed I-Claim
to I-Claim
show I-Claim
a I-Claim
benefit I-Claim
for I-Claim
up-front I-Claim
tandem I-Claim
HDCT I-Claim
compared I-Claim
with I-Claim
standard I-Claim
combination I-Claim
therapy I-Claim
. I-Claim

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti-TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

This B-Claim
study I-Claim
represents I-Claim
, I-Claim
to I-Claim
our I-Claim
knowledge I-Claim
, I-Claim
the I-Claim
largest I-Claim
analysis I-Claim
of I-Claim
HRQOL I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
factor I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

SNBM B-Claim
was I-Claim
successfully I-Claim
undertaken I-Claim
in I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
surgical I-Claim
centers I-Claim
and I-Claim
caused I-Claim
significantly I-Claim
less I-Claim
morbidity I-Claim
than I-Claim
RAC I-Claim
. I-Claim

Although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self-reported I-Claim
end-of-life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
RT I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ED I-Claim
. I-Claim

The B-Claim
new I-Claim
bone I-Claim
resorption I-Claim
markers I-Claim
of I-Claim
collagen I-Claim
breakdown I-Claim
were I-Claim
able I-Claim
to I-Claim
predict I-Claim
clinical I-Claim
response I-Claim
to I-Claim
pamidronate I-Claim
. I-Claim

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

Darbepoetin B-Claim
alfa I-Claim
, I-Claim
when I-Claim
administered I-Claim
synchronously I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
on I-Claim
an I-Claim
EDS I-Claim
appears I-Claim
to I-Claim
be I-Claim
similarly I-Claim
efficacious I-Claim
to I-Claim
darbepoetin I-Claim
alfa I-Claim
weekly I-Claim
dosing I-Claim
with I-Claim
no I-Claim
unexpected I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Our B-Claim
study I-Claim
indicates I-Claim
that I-Claim
use I-Claim
of I-Claim
rhTSH I-Claim
preserves I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
RI I-Claim
ablation I-Claim
and I-Claim
affords I-Claim
an I-Claim
ablation I-Claim
success I-Claim
rate I-Claim
comparable I-Claim
to I-Claim
that I-Claim
seen I-Claim
after I-Claim
thyroid I-Claim
hormone I-Claim
withdrawal I-Claim
. I-Claim

AT B-Claim
represents I-Claim
a I-Claim
valid I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
MBC I-Claim
. I-Claim

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4.5-month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2-positive I-Claim
MBC I-Claim
. I-Claim

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

Amenorrhea B-Claim
rates I-Claim
differed I-Claim
significantly I-Claim
by I-Claim
treatment I-Claim
arm I-Claim
, I-Claim
with I-Claim
the I-Claim
AT I-Claim
arm I-Claim
having I-Claim
the I-Claim
lowest I-Claim
rate I-Claim
. I-Claim

We B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
based I-Claim
on I-Claim
whether I-Claim
patients I-Claim
were I-Claim
allocated I-Claim
to I-Claim
receive I-Claim
misoprostol I-Claim
or I-Claim
placebo I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

Further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
QOL I-Claim
are I-Claim
critical I-Claim
. I-Claim

Methods B-Claim
are I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
professional I-Claim
time I-Claim
required I-Claim
while I-Claim
achieving I-Claim
sustained I-Claim
intervention I-Claim
effectiveness I-Claim
. I-Claim

The B-Claim
BT I-Claim
group I-Claim
, I-Claim
on I-Claim
average I-Claim
, I-Claim
experienced I-Claim
significant I-Claim
improvement I-Claim
on I-Claim
global I-Claim
sleep I-Claim
quality I-Claim
compared I-Claim
with I-Claim
the I-Claim
HEC I-Claim
group I-Claim
, I-Claim
but B-Claim
not I-Claim
on I-Claim
objective I-Claim
sleep I-Claim
or I-Claim
fatigue I-Claim
outcomes I-Claim
. I-Claim

The B-Claim
CLIP I-Claim
score I-Claim
seems I-Claim
to I-Claim
predict I-Claim
survival I-Claim
better I-Claim
than I-Claim
both I-Claim
Okuda I-Claim
and I-Claim
CTP I-Claim
score I-Claim
. I-Claim

Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

In B-Claim
phase I-Claim
II I-Claim
trials I-Claim
, I-Claim
paclitaxel I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antitumor I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

No B-Claim
appreciable I-Claim
advantage I-Claim
to I-Claim
QoL I-Claim
with I-Claim
TMX I-Claim
was I-Claim
observed I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
provides I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Gemcitabine B-Claim
plus I-Claim
carboplatin I-Claim
significantly I-Claim
improves I-Claim
PFS I-Claim
and I-Claim
response I-Claim
rate I-Claim
without I-Claim
worsening I-Claim
quality I-Claim
of I-Claim
life I-Claim
for I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

All B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co-analgesics I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim

Exploratory B-Claim
analyses I-Claim
indicate I-Claim
that I-Claim
epidermal I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
status I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
predictor I-Claim
of I-Claim
the I-Claim
erlotinib I-Claim
survival I-Claim
effect I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
KP I-Claim
or I-Claim
QOL I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Lindberg I-Claim
flap I-Claim
. I-Claim

Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

Behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim

This B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin/raltitrexed I-Claim
arm I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

In B-Claim
summary I-Claim
, I-Claim
this I-Claim
six-week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self-reported I-Claim
CRF I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim

Supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM-CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

Combined B-Claim
with I-Claim
QOL I-Claim
results I-Claim
, I-Claim
the I-Claim
significant I-Claim
increase I-Claim
in I-Claim
response I-Claim
and I-Claim
PFS I-Claim
in I-Claim
the I-Claim
CP I-Claim
arm I-Claim
and I-Claim
the I-Claim
higher I-Claim
drop-out I-Claim
rate I-Claim
in I-Claim
the I-Claim
C I-Claim
arm I-Claim
suggest I-Claim
a I-Claim
better I-Claim
outcome I-Claim
for I-Claim
the I-Claim
combination I-Claim
regimen I-Claim
despite I-Claim
its I-Claim
increased I-Claim
myelosuppression I-Claim
. I-Claim

Given B-Claim
the I-Claim
results I-Claim
of I-Claim
the I-Claim
TEAM I-Claim
trial I-Claim
, I-Claim
upfront I-Claim
use I-Claim
of I-Claim
tamoxifen I-Claim
followed I-Claim
by I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
( I-Claim
AI I-Claim
) I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
option I-Claim
for I-Claim
adjuvant I-Claim
endocrine I-Claim
therapy I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
. I-Claim

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or=2 I-Premise
g/dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30,000 I-Premise
IU I-Premise
and I-Premise
66.7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20,000 I-Premise
IU I-Premise
. I-Premise

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

The B-Premise
changes I-Premise
of I-Premise
BMD I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
p=0.011 I-Premise
, I-Premise
CI=0.063-0.437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
C I-Premise
( I-Premise
p=0.003 I-Premise
, I-Premise
CI=0.146-0.620 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
. I-Premise

Also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
Gem I-Premise
arm I-Premise
( I-Premise
7.5 I-Premise
v I-Premise
6.0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.15 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
dysuria I-Premise
had I-Premise
a I-Premise
statistically I-Premise
higher I-Premise
IPSS I-Premise
. I-Premise

Arthralgia B-Premise
and I-Premise
fatigue I-Premise
were I-Premise
less I-Premise
frequent I-Premise
, I-Premise
but I-Premise
vaginal I-Premise
discharge I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation=7.2 I-Premise
: I-Premise
mean I-Premise
EBRT=32.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
change I-Premise
in I-Premise
CES-D I-Premise
over I-Premise
the I-Premise
first I-Premise
year I-Premise
on I-Premise
survival I-Premise
out I-Premise
to I-Premise
14 I-Premise
years I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
but B-Premise
no I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
treatment I-Premise
condition I-Premise
and I-Premise
CES-D I-Premise
change I-Premise
on I-Premise
survival I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

Arm B-Premise
volume I-Premise
measured I-Premise
by I-Premise
water I-Premise
displacement I-Premise
was I-Premise
correlated I-Premise
with I-Premise
calculated I-Premise
arm I-Premise
volume I-Premise
( I-Premise
r I-Premise
=.973 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
although B-Premise
the I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
means I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

The B-Premise
3-year I-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88.2 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

Additional B-Premise
analyses I-Premise
yielded I-Premise
quadratic I-Premise
interactions I-Premise
for I-Premise
exercise I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.022 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
, I-Premise
and I-Premise
for I-Premise
stress I-Premise
management I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SM I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SM I-Premise
and I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

Treatment-related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.12 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
in I-Premise
4 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
recurrent I-Premise
obstructive I-Premise
symptoms I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
in I-Premise
5 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
1 I-Premise
in I-Premise
1 I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
reinterventions I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
in I-Premise
7 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
2 I-Premise
in I-Premise
2 I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
were I-Premise
observed I-Premise
after I-Premise
stent I-Premise
placement I-Premise
compared I-Premise
with I-Premise
GJJ I-Premise
. I-Premise

No B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FOIS I-Premise
scores I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
( I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
: I-Premise
intervention I-Premise
group I-Premise
median I-Premise
score I-Premise
, I-Premise
3 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
4 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-6 I-Premise
] I-Premise
( I-Premise
P I-Premise
= I-Premise
.88 I-Premise
) I-Premise
. I-Premise

A B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70.7 I-Premise
vs. I-Premise
68.2 I-Premise
, I-Premise
P=0.026 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

The B-Premise
unadjusted I-Premise
significance I-Premise
level I-Premise
for I-Premise
group I-Premise
differences I-Premise
was I-Premise
P I-Premise
= I-Premise
.0006 I-Premise
for I-Premise
survival I-Premise
to I-Premise
10 I-Premise
years I-Premise
. I-Premise

The B-Premise
estimated I-Premise
cost I-Premise
of I-Premise
radiotherapy I-Premise
, I-Premise
including I-Premise
retreatments I-Premise
and I-Premise
nonmedical I-Premise
costs I-Premise
, I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
for I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
than I-Premise
for I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
$ I-Premise
2438 I-Premise
versus I-Premise
$ I-Premise
3311 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
873 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
$ I-Premise
449 I-Premise
to I-Premise
$ I-Premise
1297 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
QOL I-Premise
difference I-Premise
was I-Premise
found I-Premise
, I-Premise
although I-Premise
more I-Premise
side I-Premise
effects I-Premise
occurred I-Premise
in I-Premise
CAD I-Premise
. I-Premise

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

Grade B-Premise
4/5 I-Premise
infection I-Premise
was I-Premise
observed I-Premise
in I-Premise
4.6 I-Premise
% I-Premise
of I-Premise
PE I-Premise
patients I-Premise
and I-Premise
1.8 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

The B-Premise
mean I-Premise
BAP I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
C I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Intention-to-treat B-Premise
analysis I-Premise
based I-Premise
on I-Premise
participants I-Premise
with I-Premise
follow-up I-Premise
data I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
total I-Premise
exercise I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
recommendation-only I-Premise
group I-Premise
over I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
3.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0.7-6.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.011 I-Premise
) I-Premise
. I-Premise

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

This B-Premise
difference I-Premise
, I-Premise
however I-Premise
, I-Premise
was I-Premise
not I-Premise
observed I-Premise
when I-Premise
the I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
patients I-Premise
compiled I-Premise
questionnaires I-Premise
. I-Premise

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ-C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Mean B-Premise
use I-Premise
of I-Premise
additional I-Premise
analgesia I-Premise
( I-Premise
intravenous I-Premise
morphine I-Premise
equivalents I-Premise
) I-Premise
was I-Premise
12 I-Premise
mg I-Premise
in I-Premise
the I-Premise
WIC I-Premise
arm I-Premise
and I-Premise
9 I-Premise
mg I-Premise
in I-Premise
the I-Premise
epidural I-Premise
arm I-Premise
. I-Premise

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

Body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
B I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
and I-Premise
0.01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
P=0.044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MP I-Premise
arm I-Premise
. I-Premise

Liposomal B-Premise
tretinoin I-Premise
is I-Premise
a I-Premise
new I-Premise
therapeutic I-Premise
agent I-Premise
that I-Premise
has I-Premise
been I-Premise
reported I-Premise
to I-Premise
have I-Premise
some I-Premise
clinical I-Premise
activity I-Premise
in I-Premise
patients I-Premise
with I-Premise
AIDS-associated I-Premise
Kaposi I-Premise
sarcoma I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
82.9 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
69.2 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
";" I-Premise
P I-Premise
= I-Premise
.031 I-Premise
) I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
58.0 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
51.7 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise

Increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
EBRT I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42.9 I-Premise
% I-Premise
v I-Premise
15.2 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
";" I-Premise
HR I-Premise
= I-Premise
2.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.41 I-Premise
to I-Premise
3.20 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Several B-Premise
aspects I-Premise
of I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
rated I-Premise
to I-Premise
be I-Premise
better I-Premise
in I-Premise
group I-Premise
B I-Premise
than I-Premise
in I-Premise
group I-Premise
A I-Premise
, I-Premise
although B-Premise
not I-Premise
all I-Premise
differences I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

AET B-Premise
did I-Premise
not I-Premise
interfere I-Premise
with I-Premise
chemotherapy I-Premise
completion I-Premise
rate I-Premise
or I-Premise
treatment I-Premise
response I-Premise
. I-Premise

The B-Premise
RRs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6.7 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.8-16.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13,558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.4 I-Premise
years I-Premise
, I-Premise
132 I-Premise
patients I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
98 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
had I-Premise
died I-Premise
";" I-Premise
the B-Premise
number I-Premise
of I-Premise
deaths I-Premise
due I-Premise
to I-Premise
prostate I-Premise
cancer I-Premise
was I-Premise
47 I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
29 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
. I-Premise

In B-Premise
the I-Premise
UAE I-Premise
group I-Premise
, I-Premise
mean I-Premise
Â± I-Premise
standard I-Premise
deviation I-Premise
uterine I-Premise
volume I-Premise
was I-Premise
670 I-Premise
Â± I-Premise
503 I-Premise
, I-Premise
422 I-Premise
Â± I-Premise
353 I-Premise
, I-Premise
and I-Premise
292 I-Premise
Â± I-Premise
287 I-Premise
mL I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
VEGF I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
groups I-Premise
that I-Premise
included I-Premise
CBT I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.39-0.56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
habit I-Premise
subscale I-Premise
";" I-Premise
P=.027 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
";" I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

Ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low-dose I-Premise
radioiodine I-Premise
versus I-Premise
88.9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175-mg/m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.2 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
women I-Premise
treated I-Premise
with I-Premise
160 I-Premise
mg/d I-Premise
reported I-Premise
less I-Premise
severe I-Premise
side I-Premise
effects I-Premise
( I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
better I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
FLS I-Premise
, I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
less I-Premise
psychologic I-Premise
distress I-Premise
( I-Premise
MHI I-Premise
, I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FLIC I-Premise
, I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
from I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
as I-Premise
compared I-Premise
with I-Premise
those I-Premise
treated I-Premise
with I-Premise
1,600 I-Premise
mg/d I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

No B-Premise
group-related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise

Intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self-efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
A I-Premise
. I-Premise

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
in I-Premise
participants I-Premise
who I-Premise
died I-Premise
during I-Premise
the I-Premise
study I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
3.6 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-24.2 I-Premise
( I-Premise
20.5 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
) I-Premise
, I-Premise
and I-Premise
-2.7 I-Premise
( I-Premise
1.2 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
different I-Premise
schedules I-Premise
of I-Premise
vinorelbine I-Premise
in I-Premise
the I-Premise
two I-Premise
arms I-Premise
led I-Premise
to I-Premise
a I-Premise
greater I-Premise
survival I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
without I-Premise
impairing I-Premise
the I-Premise
tolerance I-Premise
profile I-Premise
, I-Premise
although B-Premise
this I-Premise
is I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

Compared B-Premise
only I-Premise
with I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
responders I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
baseline I-Premise
QL I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
328.5 I-Premise
v I-Premise
340 I-Premise
days I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
âˆ¼11 I-Premise
% I-Premise
";" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
âˆ¼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
âˆ¼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
âˆ¼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
âˆ¼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
longitudinal I-Premise
changes I-Premise
were I-Premise
detected I-Premise
in I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
in I-Premise
both I-Premise
groups I-Premise
upon I-Premise
available I-Premise
follow-up I-Premise
. I-Premise

However B-Premise
, I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
substantially I-Premise
less I-Premise
overall I-Premise
and I-Premise
grade I-Premise
2 I-Premise
or I-Premise
higher I-Premise
neurotoxicity I-Premise
than I-Premise
paclitaxel-carboplatin I-Premise
( I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neurosensory I-Premise
toxicity I-Premise
in I-Premise
11 I-Premise
% I-Premise
versus I-Premise
30 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neuromotor I-Premise
toxicity I-Premise
in I-Premise
3 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
% I-Premise
to I-Premise
7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43.1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
44.5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
1.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.18 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.885 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
mean I-Premise
volume I-Premise
change I-Premise
between I-Premise
randomisation I-Premise
groups I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.6 I-Premise
) I-Premise
, I-Premise
-1.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.1 I-Premise
to I-Premise
3.5 I-Premise
) I-Premise
, I-Premise
nor I-Premise
was I-Premise
there I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
response I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.7 I-Premise
) I-Premise
, I-Premise
where I-Premise
mean I-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
treatment I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
-2.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-7.9 I-Premise
to I-Premise
3.4 I-Premise
) I-Premise
and I-Premise
-1.1 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-3.9 I-Premise
to I-Premise
1.7 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
HRQOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
global I-Premise
QL I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
QL I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
toxicity I-Premise
. I-Premise

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3-year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
( I-Premise
5.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1.6 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
. I-Premise

Kaplan-Meier B-Premise
survival I-Premise
curves I-Premise
demonstrated I-Premise
better I-Premise
survival I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
than I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

In B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDI I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late-alternation I-Premise
arm I-Premise
. I-Premise

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
-24 I-Premise
and I-Premise
3-hour I-Premise
groups I-Premise
( I-Premise
19 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.6 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
benefits I-Premise
in I-Premise
analgesia I-Premise
were I-Premise
found I-Premise
in I-Premise
the I-Premise
global I-Premise
pain I-Premise
intensity I-Premise
of I-Premise
the I-Premise
previous I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
the I-Premise
least I-Premise
pain I-Premise
intensity I-Premise
or I-Premise
the I-Premise
pain I-Premise
evaluated I-Premise
just I-Premise
after I-Premise
a I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
at I-Premise
the I-Premise
moment I-Premise
of I-Premise
the I-Premise
visit I-Premise
, I-Premise
when I-Premise
amitriptyline I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
reason I-Premise
for I-Premise
dropout I-Premise
was I-Premise
patients I-Premise
feeling I-Premise
too I-Premise
ill I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
reached I-Premise
8 I-Premise
months I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
9 I-Premise
months I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

Among B-Premise
the I-Premise
clinical I-Premise
outcome I-Premise
measures I-Premise
, I-Premise
QOL I-Premise
score I-Premise
improvement I-Premise
was I-Premise
greater I-Premise
for I-Premise
UAE I-Premise
with I-Premise
TAGMs I-Premise
compared I-Premise
with I-Premise
PVA I-Premise
( I-Premise
49.0 I-Premise
vs I-Premise
27.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
but B-Premise
no I-Premise
other I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
BMI I-Premise
significantly I-Premise
deteriorated I-Premise
compared I-Premise
with I-Premise
preoperative I-Premise
BMI I-Premise
in I-Premise
each I-Premise
group I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
non-hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

A B-Premise
higher I-Premise
rate I-Premise
of I-Premise
persistent I-Premise
thyroid I-Premise
remnants I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
arm I-Premise
, I-Premise
although B-Premise
in I-Premise
most I-Premise
cases I-Premise
uptake I-Premise
was I-Premise
< I-Premise
0.1 I-Premise
% I-Premise
and I-Premise
of I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Change B-Premise
in I-Premise
self-efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
's I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
4.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
5.0 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5.6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.4 I-Premise
to I-Premise
6.7 I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
preference I-Premise
for I-Premise
the I-Premise
two I-Premise
treatment I-Premise
periods I-Premise
were I-Premise
found I-Premise
. I-Premise

Changes B-Premise
in I-Premise
resting I-Premise
energy I-Premise
expenditure I-Premise
and I-Premise
biochemical I-Premise
tests I-Premise
did I-Premise
not I-Premise
differ I-Premise
during I-Premise
follow-up I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6-minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
for I-Premise
gemcitabine-carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
7.9-9.7 I-Premise
months I-Premise
) I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5.2-7.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0.72 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.58-0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0032 I-Premise
] I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
and I-Premise
55.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

When B-Premise
participants I-Premise
in I-Premise
the I-Premise
sham I-Premise
acupuncture I-Premise
group I-Premise
were I-Premise
crossed I-Premise
over I-Premise
to I-Premise
TRUE I-Premise
acupuncture I-Premise
, I-Premise
a I-Premise
further I-Premise
reduction I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
was I-Premise
seen I-Premise
. I-Premise

No B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0-10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1-month I-Premise
outcomes I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p=0.022 I-Premise
) I-Premise
. I-Premise

Results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
MBAT I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post-intervention I-Premise
";" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post-intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

Nausea B-Premise
and I-Premise
vomiting I-Premise
frequency I-Premise
, I-Premise
duration I-Premise
, I-Premise
and I-Premise
distress I-Premise
were I-Premise
lower I-Premise
for I-Premise
experimental I-Premise
group I-Premise
members I-Premise
, I-Premise
although B-Premise
a I-Premise
high I-Premise
attrition I-Premise
rate I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
resulted I-Premise
in I-Premise
insufficient I-Premise
power I-Premise
to I-Premise
detect I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
over I-Premise
time I-Premise
. I-Premise

In B-Premise
the I-Premise
IAD I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise

Postoperative B-Premise
side I-Premise
effects I-Premise
were I-Premise
significantly I-Premise
less I-Premise
in I-Premise
the I-Premise
SLN I-Premise
group I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
SLN I-Premise
procedure I-Premise
on I-Premise
psychologic I-Premise
well I-Premise
being I-Premise
. I-Premise

Reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
ORRs I-Premise
were I-Premise
48.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38.5 I-Premise
% I-Premise
-59.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58.7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
47.9 I-Premise
% I-Premise
-68.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.117 I-Premise
) I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
12 I-Premise
months I-Premise
and I-Premise
382 I-Premise
deaths I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
clear I-Premise
survival I-Premise
benefit I-Premise
when I-Premise
comparing I-Premise
PCV I-Premise
with I-Premise
TMZ I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.74 I-Premise
to I-Premise
1.11 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.350 I-Premise
) I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

Decreased B-Premise
quality I-Premise
of I-Premise
life I-Premise
later I-Premise
after I-Premise
treatment I-Premise
was I-Premise
also I-Premise
observed I-Premise
in I-Premise
patients I-Premise
diagnosed I-Premise
with I-Premise
unresectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
the I-Premise
same I-Premise
regimen I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
EBRT I-Premise
reported I-Premise
significantly I-Premise
higher I-Premise
levels I-Premise
of I-Premise
diarrhea I-Premise
and I-Premise
bowel I-Premise
symptoms I-Premise
. I-Premise

The B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

Major B-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
groups I-Premise
. I-Premise

Comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise

The B-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0.16 I-Premise
to I-Premise
2.45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0.66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

In B-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
liver I-Premise
volume I-Premise
increased I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
from I-Premise
4689 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
613-8765 I-Premise
mL I-Premise
) I-Premise
to I-Premise
4895 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
739-9053 I-Premise
mL I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine-carboplatin I-Premise
group I-Premise
was I-Premise
47.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
39.9-54.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30.9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
24.1-37.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0016 I-Premise
) I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
overall I-Premise
survival I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
( I-Premise
median I-Premise
, I-Premise
16.2 I-Premise
v I-Premise
14.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

A B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
( I-Premise
complete I-Premise
[ I-Premise
CR I-Premise
] I-Premise
or I-Premise
partial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
was I-Premise
obtained I-Premise
in I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
, I-Premise
and I-Premise
7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CEF I-Premise
, I-Premise
E I-Premise
, I-Premise
M I-Premise
, I-Premise
and I-Premise
MV I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
nutritional I-Premise
condition I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
was I-Premise
nearly I-Premise
the I-Premise
same I-Premise
as I-Premise
that I-Premise
in I-Premise
the I-Premise
RY I-Premise
group I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AE I-Premise
";" I-Premise
78.0 I-Premise
% I-Premise
vs I-Premise
79.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
serious I-Premise
AE I-Premise
( I-Premise
11.1 I-Premise
% I-Premise
vs I-Premise
9.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
discontinuations I-Premise
due I-Premise
to I-Premise
AE I-Premise
( I-Premise
3.8 I-Premise
% I-Premise
vs I-Premise
4.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
serious I-Premise
AE I-Premise
( I-Premise
2.0 I-Premise
% I-Premise
vs I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
were I-Premise
comparable I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

PFS B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0.57 I-Premise
";" I-Premise
p=0.0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
IHC-positive I-Premise
disease I-Premise
( I-Premise
HR=0.50 I-Premise
";" I-Premise
p=0.0057 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon-alfa-treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon-alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.00 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.81-1.24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin-2 I-Premise
and I-Premise
245 I-Premise
noninterleukin-2-treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.07 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87-1.33 I-Premise
";" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0.99 I-Premise
and I-Premise
0.52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.77 I-Premise
) I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow-up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
post-randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
recommendation-plus-referral I-Premise
group I-Premise
and I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.5 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.0 I-Premise
to I-Premise
4.0 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.244 I-Premise
) I-Premise
. I-Premise

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM-CSF-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i.e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Anemia B-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
hematological I-Premise
toxicity I-Premise
( I-Premise
88 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
";" I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

During B-Premise
the I-Premise
study I-Premise
, I-Premise
31.7 I-Premise
% I-Premise
of I-Premise
placebo-treated I-Premise
patients I-Premise
achieved I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
HgB I-Premise
increase I-Premise
compared I-Premise
with I-Premise
72.7 I-Premise
% I-Premise
of I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

The B-Premise
advantage I-Premise
lasted I-Premise
for I-Premise
all I-Premise
the I-Premise
duration I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.75-1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.7349 I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.7349 I-Premise
) I-Premise
. I-Premise

At B-Premise
1 I-Premise
year I-Premise
, I-Premise
symptom I-Premise
scores I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
. I-Premise

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
baseline I-Premise
neutrophil I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
baseline I-Premise
platelet I-Premise
counts I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
the I-Premise
difference I-Premise
between I-Premise
white I-Premise
blood I-Premise
cell I-Premise
( I-Premise
WBC I-Premise
) I-Premise
and I-Premise
neutrophil I-Premise
count I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
had I-Premise
a I-Premise
significant I-Premise
adverse I-Premise
prognostic I-Premise
value I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0.2-13.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

While B-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
functional I-Premise
and I-Premise
cognitive I-Premise
functioning I-Premise
scores I-Premise
appeared I-Premise
to I-Premise
be I-Premise
improved I-Premise
only I-Premise
in I-Premise
patients I-Premise
of I-Premise
group I-Premise
I I-Premise
. I-Premise

The B-Premise
FFM/FM I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Mild B-Premise
or I-Premise
moderate I-Premise
nausea I-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
side I-Premise
effect I-Premise
of I-Premise
estramustine I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non-stent-treated I-Premise
patients I-Premise
( I-Premise
log-rank I-Premise
statistic=4.21 I-Premise
, I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
unexpected I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
. I-Premise

As B-Premise
reflected I-Premise
in I-Premise
the I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
, I-Premise
patients I-Premise
in I-Premise
all I-Premise
three I-Premise
treatment I-Premise
groups I-Premise
experienced I-Premise
induced I-Premise
amenorrhea I-Premise
, I-Premise
but B-Premise
the I-Premise
onset I-Premise
of I-Premise
ovarian I-Premise
function I-Premise
suppression I-Premise
was I-Premise
slightly I-Premise
delayed I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3-month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

Although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise

Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
34 I-Premise
and I-Premise
33.7 I-Premise
months I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.68 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
5-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.94 I-Premise
) I-Premise
. I-Premise

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

We B-Premise
recorded I-Premise
no I-Premise
CBT-related I-Premise
adverse I-Premise
events I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
relationships I-Premise
between I-Premise
biomarker I-Premise
expression I-Premise
and I-Premise
outcomes I-Premise
were I-Premise
observed I-Premise
. I-Premise

CBR B-Premise
was I-Premise
45.6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
39.6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
250 I-Premise
mg. I-Premise
DoCB B-Premise
and I-Premise
OS I-Premise
were I-Premise
16.6 I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
500-mg I-Premise
group I-Premise
, I-Premise
whereas I-Premise
DoCB I-Premise
and I-Premise
OS I-Premise
were I-Premise
13.9 I-Premise
and I-Premise
22.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
250-mg I-Premise
group I-Premise
. I-Premise

The B-Premise
3-year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94.1 I-Premise
% I-Premise
and I-Premise
67.7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.24 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.078 I-Premise
to I-Premise
0.73 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Two B-Premise
toxicity-related I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
3.9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4-year I-Premise
recurrence-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67.5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
62.7 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.19 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.095 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
was I-Premise
statistically I-Premise
lower I-Premise
compared I-Premise
to I-Premise
that I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
LV5FU2 I-Premise
or I-Premise
ldLV5FU2 I-Premise
( I-Premise
combined I-Premise
group I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

Both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
CVP I-Premise
";" I-Premise
P I-Premise
=.95 I-Premise
) I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
G1 I-Premise
all I-Premise
QoL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
whereas I-Premise
in I-Premise
G2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
G3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Rates B-Premise
of I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
25.6 I-Premise
and I-Premise
23.4 I-Premise
per I-Premise
100 I-Premise
patient-years I-Premise
in I-Premise
the I-Premise
double-blind I-Premise
versus I-Premise
cumulative I-Premise
period I-Premise
. I-Premise

Lower B-Premise
scores I-Premise
were I-Premise
associated I-Premise
with I-Premise
the I-Premise
combination I-Premise
therapy I-Premise
. I-Premise

Longitudinal B-Premise
analyses I-Premise
replicated I-Premise
these I-Premise
findings I-Premise
. I-Premise

Changes B-Premise
from I-Premise
baseline I-Premise
in I-Premise
several I-Premise
quality I-Premise
of I-Premise
life I-Premise
variables I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
periodically I-Premise
from I-Premise
months I-Premise
1 I-Premise
to I-Premise
6 I-Premise
, I-Premise
and I-Premise
all I-Premise
favored I-Premise
bicalutamide I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
53.6 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
decreasing I-Premise
CES-D I-Premise
scores I-Premise
over I-Premise
1 I-Premise
year I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
increasing I-Premise
CES-D I-Premise
scores I-Premise
. I-Premise

Psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49.6 I-Premise
to I-Premise
61.2 I-Premise
vs. I-Premise
50.1 I-Premise
to I-Premise
51.5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non-responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept-treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59.4 I-Premise
% I-Premise
and I-Premise
56.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23.5 I-Premise
% I-Premise
and I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11.5 I-Premise
% I-Premise
and I-Premise
16.1 I-Premise
% I-Premise
";" I-Premise
HAQ-DI I-Premise
responses I-Premise
were I-Premise
54.4 I-Premise
% I-Premise
and I-Premise
47.9 I-Premise
% I-Premise
. I-Premise

Post-treatment B-Premise
symptoms I-Premise
were I-Premise
increased I-Premise
above I-Premise
baseline I-Premise
for I-Premise
all I-Premise
treatments I-Premise
. I-Premise

Comparison B-Premise
of I-Premise
the I-Premise
population I-Premise
norm I-Premise
and I-Premise
clinical I-Premise
trial I-Premise
data I-Premise
showed I-Premise
that I-Premise
treatment I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
resulted I-Premise
in I-Premise
clinically I-Premise
meaningful I-Premise
as I-Premise
well I-Premise
as I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19.5 I-Premise
% I-Premise
vs. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8.2 I-Premise
, I-Premise
7.0 I-Premise
, I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Clinically B-Premise
relevant I-Premise
improvements I-Premise
in I-Premise
symptoms I-Premise
and I-Premise
mood I-Premise
disturbance I-Premise
were I-Premise
seen I-Premise
for I-Premise
both I-Premise
groups I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
";" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

Despite B-Premise
difficulties I-Premise
in I-Premise
carrying I-Premise
out I-Premise
and I-Premise
analysing I-Premise
QoL I-Premise
items I-Premise
in I-Premise
such I-Premise
patients I-Premise
, I-Premise
the I-Premise
global I-Premise
QoL I-Premise
evaluated I-Premise
by I-Premise
the I-Premise
Spitzer I-Premise
's I-Premise
questionnaire I-Premise
suggested I-Premise
an I-Premise
advantage I-Premise
for I-Premise
MVC I-Premise
regimen I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
and I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
global I-Premise
health I-Premise
subdomain I-Premise
( I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
EQ-5D I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise

Incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or=2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

Immediate B-Premise
lung I-Premise
expansion I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
radiologic I-Premise
recurrence I-Premise
, I-Premise
clinical I-Premise
recurrence I-Premise
, I-Premise
or I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0.60 I-Premise
, I-Premise
0.15 I-Premise
, I-Premise
and I-Premise
0.20 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A B-Premise
slight I-Premise
increase I-Premise
in I-Premise
transfusions I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
. I-Premise

Epoetin B-Premise
alfa I-Premise
recipients I-Premise
had I-Premise
less I-Premise
of I-Premise
a I-Premise
decrease I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
and I-Premise
improvement I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26Â·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19Â·3-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18Â·4 I-Premise
months I-Premise
[ I-Premise
14Â·9-not I-Premise
estimable I-Premise
] I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0Â·82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0Â·67-1Â·00 I-Premise
";" I-Premise
p=0Â·0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10Â·3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9Â·3-13Â·0 I-Premise
] I-Premise
vs I-Premise
7Â·4 I-Premise
months I-Premise
[ I-Premise
6Â·4-8Â·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0Â·79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0Â·67-0Â·93 I-Premise
";" I-Premise
p=0Â·005 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
more I-Premise
treatment I-Premise
cycles I-Premise
with I-Premise
docetaxel I-Premise
( I-Premise
TC I-Premise
, I-Premise
49 I-Premise
% I-Premise
";" I-Premise
TCF I-Premise
, I-Premise
57 I-Premise
% I-Premise
";" I-Premise
ECF I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
EXE I-Premise
( I-Premise
median I-Premise
not I-Premise
reached I-Premise
) I-Premise
than I-Premise
with I-Premise
MA I-Premise
( I-Premise
123.4 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.039 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
the I-Premise
median I-Premise
duration I-Premise
of I-Premise
overall I-Premise
success I-Premise
( I-Premise
OR I-Premise
or I-Premise
stable I-Premise
disease I-Premise
> I-Premise
or I-Premise
= I-Premise
24 I-Premise
weeks I-Premise
";" I-Premise
60.1 I-Premise
v I-Premise
49.1 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.025 I-Premise
) I-Premise
, I-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
( I-Premise
20.3 I-Premise
v I-Premise
16.6 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
16.3 I-Premise
v I-Premise
15.7 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.042 I-Premise
) I-Premise
. I-Premise

Four B-Premise
toxic I-Premise
deaths I-Premise
occurred I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
and I-Premise
eight I-Premise
in I-Premise
the I-Premise
NIP I-Premise
arm I-Premise
. I-Premise

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6.0 I-Premise
, I-Premise
9.0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.0 I-Premise
, I-Premise
10.0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
occurred I-Premise
in I-Premise
50 I-Premise
% I-Premise
and I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
PE I-Premise
patients I-Premise
in I-Premise
step I-Premise
1 I-Premise
and I-Premise
60 I-Premise
% I-Premise
and I-Premise
13 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
in I-Premise
step I-Premise
2 I-Premise
. I-Premise

The B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14.9 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
with I-Premise
low I-Premise
TS I-Premise
, I-Premise
no I-Premise
remarkable I-Premise
difference I-Premise
in I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
was I-Premise
observed I-Premise
. I-Premise

Vinorelbine-treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer-related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity-related I-Premise
symptoms I-Premise
. I-Premise

In B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow-up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
";" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second-line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5-FU I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
scores I-Premise
at I-Premise
months I-Premise
9 I-Premise
and I-Premise
12 I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
and I-Premise
P I-Premise
= I-Premise
.93 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
of I-Premise
both I-Premise
the I-Premise
FLIC I-Premise
and I-Premise
FACT-L I-Premise
demonstrated I-Premise
significantly I-Premise
lower I-Premise
scores I-Premise
corresponding I-Premise
to I-Premise
lower I-Premise
KPS I-Premise
values I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.016 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
net I-Premise
balance I-Premise
resulted I-Premise
in I-Premise
$ I-Premise
351 I-Premise
extra I-Premise
cost I-Premise
per I-Premise
patient I-Premise
randomly I-Premise
allocated I-Premise
to I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
. I-Premise

Percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
SOC I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
v I-Premise
22.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
, I-Premise
67 I-Premise
% I-Premise
rated I-Premise
GI I-Premise
as I-Premise
good I-Premise
, I-Premise
very I-Premise
good I-Premise
, I-Premise
or I-Premise
excellent I-Premise
. I-Premise

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

During B-Premise
follow-up I-Premise
, I-Premise
71 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
showed I-Premise
unaltered I-Premise
or I-Premise
improved I-Premise
lung I-Premise
expansion I-Premise
and I-Premise
9 I-Premise
patients I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
needed I-Premise
new I-Premise
pleural I-Premise
procedures I-Premise
( I-Premise
VATS I-Premise
group I-Premise
, I-Premise
5 I-Premise
recurrences I-Premise
";" I-Premise
TS I-Premise
group I-Premise
, I-Premise
4 I-Premise
recurrences I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.999 I-Premise
) I-Premise
. I-Premise

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
Ï‡1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
Ï‡1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

Self-reported B-Premise
time I-Premise
spent I-Premise
on I-Premise
hair I-Premise
removal I-Premise
declined I-Premise
from I-Premise
112 I-Premise
to I-Premise
21 I-Premise
min I-Premise
per I-Premise
week I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
from I-Premise
92 I-Premise
to I-Premise
56 I-Premise
min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
/= I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
infusion I-Premise
site I-Premise
pain I-Premise
( I-Premise
10 I-Premise
% I-Premise
v I-Premise
0.5 I-Premise
% I-Premise
) I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
ASA404 I-Premise
arm I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise

Maximum B-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
were I-Premise
normalized I-Premise
within I-Premise
6 I-Premise
months I-Premise
postoperatively I-Premise
in I-Premise
all I-Premise
groups I-Premise
. I-Premise

At B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0.37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1.0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
AMA I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2.21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-2.59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-4.3 I-Premise
to I-Premise
-0.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
4.46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-5.6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-8.9 I-Premise
to I-Premise
-2.2 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

The B-Premise
adherence I-Premise
rate I-Premise
to I-Premise
ALT I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
the I-Premise
adherence I-Premise
to I-Premise
self-management I-Premise
therapy I-Premise
. I-Premise

Time B-Premise
to I-Premise
5 I-Premise
% I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
significantly I-Premise
favored I-Premise
DCF I-Premise
over I-Premise
CF I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
after I-Premise
12 I-Premise
months I-Premise
subscale I-Premise
scores I-Premise
for I-Premise
role-physical I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
, I-Premise
and I-Premise
physical I-Premise
function I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
indicating I-Premise
a I-Premise
better I-Premise
condition I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Total B-Premise
costs I-Premise
per I-Premise
patient I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro12433 I-Premise
vs. I-Premise
euro8819 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
without I-Premise
pain I-Premise
had I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

However B-Premise
, I-Premise
a I-Premise
trend I-Premise
for I-Premise
more I-Premise
favorable I-Premise
overall I-Premise
survival I-Premise
was I-Premise
documented I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
, I-Premise
although B-Premise
the I-Premise
P I-Premise
value I-Premise
was I-Premise
of I-Premise
borderline I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

CR B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Fifty-nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise

Drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.036 I-Premise
, I-Premise
0.003 I-Premise
, I-Premise
and I-Premise
0.034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
the I-Premise
ORR I-Premise
, I-Premise
DCR I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
exhibited I-Premise
no I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Dyspnea B-Premise
, I-Premise
fatigue I-Premise
and I-Premise
coughing I-Premise
domains I-Premise
were I-Premise
worse I-Premise
in I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
at I-Premise
baseline I-Premise
. I-Premise

Self-reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7.3 I-Premise
to I-Premise
3.6 I-Premise
over I-Premise
the I-Premise
6-month I-Premise
study I-Premise
period I-Premise
";" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7.1 I-Premise
and I-Premise
6.1 I-Premise
. I-Premise

TSS B-Premise
improved I-Premise
in I-Premise
49 I-Premise
patients I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
, I-Premise
a I-Premise
difference I-Premise
of I-Premise
15 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
3-28 I-Premise
) I-Premise
in I-Premise
the I-Premise
proportion I-Premise
improving I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.2 I-Premise
to I-Premise
15.0 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
13.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.4 I-Premise
to I-Premise
15.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13.7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.0 I-Premise
to I-Premise
16.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.724 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
and I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.8 I-Premise
to I-Premise
4.6 I-Premise
months I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.6 I-Premise
to I-Premise
11.1 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
4.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.5 I-Premise
to I-Premise
6.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
9.5 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
6.9 I-Premise
to I-Premise
12.2 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-cisplatin I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
and I-Premise
6.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.5 I-Premise
to I-Premise
8.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.3 I-Premise
to I-Premise
13.3 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-irinotecan I-Premise
, I-Premise
respectively I-Premise
. I-Premise

From O
February O
1998 O
to O
June O
1999 O
, O
259 O
chemonaÃ¯ve O
patients O
entered O
the O
study O
and O
were O
randomised O
to O
receive O
either O
vinorelbine-cisplatin O
( O
NP O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
and O
15 O
with O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
or O
vinorelbine-ifosfamide-cisplatin O
( O
NIP O
";" O
vinorelbine O
25 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
ifosfamide O
3 O
g/m O
( O
2 O
) O
on O
day O
1 O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
with O
both O
regimens O
being O
repeated O
every O
3 O
weeks O
. O

269 O
patients O
with O
cancer O
";" O
73 O
men O
, O
196 O
women O
, O
mean O
age O
47 O
years O
( O
range O
20-65 O
) O
representing O
21 O
diagnoses O
. O

108 O
, O
111 O
, O
and O
107 O
patients O
, O
respectively O
, O
were O
analysed O
. O

Differences O
between O
the O
groups O
over O
time O
were O
assessed O
by O
using O
mixed O
modeling O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

The O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
. O

Thalidomide O
with O
melphalan/prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

A O
phase O
III O
study O
to O
definitively O
test O
this O
neoadjuvant-concurrent O
strategy O
is O
warranted O
. O

Future O
studies O
can O
provide O
further O
insight O
on O
how O
to O
tailor O
QOL O
interventions O
for O
these O
age O
groups O
. O

Patients O
' O
experiences O
and O
adherence O
to O
the O
topical O
agents O
were O
also O
evaluated O
. O

With O
the O
adoption O
of O
enhanced O
recovery O
and O
emerging O
new O
modalities O
of O
analgesia O
after O
laparoscopic O
colorectal O
resection O
( O
LCR O
) O
, O
the O
role O
of O
epidural O
analgesia O
has O
been O
questioned O
. O

The O
general O
exercise O
group O
performed O
body O
conditioning O
exercise O
. O

Consenting O
patients O
( O
N O
= O
271 O
) O
with O
a O
preliminary O
diagnosis O
of O
cancer O
of O
the O
esophagus O
, O
stomach O
, O
liver/gallbladder O
, O
pancreas O
, O
or O
colon/rectum O
were O
stratified O
by O
sex O
and O
randomly O
assigned O
to O
a O
control O
group O
that O
received O
standard O
care O
as O
provided O
on O
the O
surgical O
wards O
, O
or O
to O
an O
experimental O
group O
that O
received O
formal O
psychotherapeutic O
support O
in O
addition O
to O
routine O
care O
during O
the O
hospital O
stay O
. O

Assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O

Phase O
III O
EGF104900 O
data O
demonstrated O
that O
lapatinib O
plus O
trastuzumab O
significantly O
improved O
progression-free O
survival O
( O
PFS O
) O
and O
clinical O
benefit O
rate O
versus O
lapatinib O
monotherapy O
, O
offering O
a O
chemotherapy-free O
option O
for O
patients O
with O
heavily O
pretreated O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

BT O
plans O
were O
revised O
before O
each O
CTX O
and O
30 O
, O
60 O
, O
and O
90 O
days O
after O
the O
last O
CTX O
and O
reinforced O
7 O
to O
9 O
days O
later O
. O

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21-day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

Between O
1999 O
and O
2002 O
, O
83 O
patients O
were O
recruited O
into O
the O
study O
at O
Westmead O
and O
Nepean O
Hospitals O
, O
Sydney O
. O

These O
samples O
were O
analyzed O
using O
six O
polymorphic O
DNA O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O

Women O
were O
recruited O
to O
the O
study O
during O
their O
final O
week O
of O
treatment O
. O

This O
study O
examined O
the O
characteristics O
of O
women O
enrolled O
in O
an O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
, O
and O
explored O
the O
relationship O
between O
sexual O
functioning O
and O
psychological O
well-being O
. O

Exercise O
therapies O
were O
performed O
for O
one O
session O
per O
week O
for O
eight O
weeks O
. O

A O
prospective O
randomized O
, O
controlled O
pilot O
trial O
with O
historical O
control O
. O

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O

Proportions O
of O
patients O
with O
skeletal-related O
events O
, O
time O
to O
the O
first O
skeletal-related O
event O
, O
skeletal O
morbidity O
rate O
, O
pain O
and O
analgesic O
scores O
, O
disease O
progression O
, O
and O
safety O
were O
assessed O
. O

Gastrojejunostomy O
( O
GJJ O
) O
and O
stent O
placement O
are O
the O
most O
commonly O
used O
palliative O
treatments O
for O
malignant O
gastric O
outlet O
obstruction O
( O
GOO O
) O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

Data O
were O
analyzed O
with O
use O
of O
t O
tests O
, O
the O
Mann-Whitney O
U O
test O
, O
and O
chi2 O
tests O
as O
appropriate O
. O

An O
open O
, O
randomized O
study O
was O
performed O
to O
assess O
the O
effects O
of O
supportive O
pamidronate O
treatment O
on O
morbidity O
from O
bone O
metastases O
in O
breast O
cancer O
patients O
. O

All O
had O
chemotherapy O
. O

From O
January O
2000 O
to O
July O
2004 O
, O
492 O
patients O
were O
enrolled O
. O

Tumor O
treatment O
was O
unrestricted O
. O

( O
From O
April O
1996 O
to O
November O
1997 O
, O
191 O
of O
the O
350 O
targeted O
patients O
were O
randomly O
assigned O
. O
) O

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

Profile O
of O
Mood O
States O
( O
POMS O
";" O
primary O
outcome O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-Endocrine O
Symptoms O
( O
FACT-ES O
) O
scales O
and O
the O
WHO O
five-item O
well-being O
questionnaire O
( O
WHO-5 O
) O
evaluated O
mood O
, O
quality O
of O
life O
, O
and O
well-being O
at O
weeks O
0 O
, O
8 O
, O
and O
12 O
. O

A O
number O
of O
studies O
testing O
alpha-tocopherol O
( O
vitamin O
E O
) O
and O
pentoxifylline O
suggest O
evidence O
of O
clinical O
regression O
of O
superficial O
radiation-induced O
fibrosis O
but O
there O
is O
only O
very O
limited O
evidence O
from O
randomised O
trials O
. O

Patients O
given O
GC O
received O
more O
chemotherapy O
as O
outpatients O
( O
89 O
% O
GC O
vs O
66 O
% O
PE O
of O
treatment O
cycles O
) O
. O

Breast O
cancer O
patients O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
randomly O
assigned O
to O
usual O
care O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
";" O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
78 O
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O

This O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
PRBCs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
QOL O
) O
and O
complete O
remission O
( O
CR O
) O
rates O
. O

One O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
AM O
( O
n O
= O
54 O
) O
or O
PM O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8.3 O
months O
. O

Paired O
t O
tests O
were O
performed O
for O
within-group O
analysis O
. O

Each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
";" O
an O
overall O
P O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O

( O
7,000 O
mg/m O
( O
2 O
) O
day O
1 O
of O
a O
28-day O
cycle O
) O
or O
p.o O
. O

Tablets O
were O
unrecognizable O
for O
drug O
assignment O
. O

Chemotherapy O
with O
a O
platinum O
agent O
and O
a O
taxane O
( O
paclitaxel O
) O
is O
considered O
the O
standard O
of O
care O
for O
treatment O
of O
ovarian O
carcinoma O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Safety O
was O
also O
assessed O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal-dominant O
( O
AD O
) O
PKD O
or O
autosomal-dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

Participants O
were O
enrolled O
in O
a O
randomized O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
and O
completed O
outcome O
measures O
prior O
to O
randomization O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
these O
treatments O
on O
health-related O
quality O
of O
life O
( O
HQL O
) O
. O

Randomly O
assigned O
patients O
were O
to O
receive O
four O
cycles O
, O
each O
at O
3-week O
intervals O
, O
of O
carboplatin O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
plus O
gemcitabine O
1,200 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
GCa O
) O
or O
mitomycin O
6 O
mg/m O
( O
2 O
) O
, O
ifosfamide O
3g/m O
( O
2 O
) O
, O
and O
cisplatin O
50 O
mg/m O
( O
2 O
) O
on O
day O
1 O
( O
MIC O
) O
. O

Body O
image O
and O
QOL O
also O
were O
assessed O
preoperatively O
. O

At O
6-month O
follow-up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
quality O
of O
life O
, O
self-esteem O
, O
fatigue O
, O
anxiety O
, O
depression O
, O
and O
exercise O
behavior O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Patients O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
ES O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

All O
patients O
were O
chemotherapy-naÃ¯ve O
and O
had O
an O
ECOG O
performance O
status O
( O
PS O
) O
of O
0-1 O
. O

Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

They O
were O
all O
reconstructed O
with O
stomach O
interposition O
through O
the O
retrosternal O
route O
. O

Two-hundred O
and O
seven O
patients O
from O
18 O
centres O
were O
randomised O
: O
103 O
in O
the O
FU O
arm O
and O
104 O
in O
FUP O
arm O
. O

Cancer O
patients O
with O
baseline O
" O
worst O
pain O
" O
of O
â‰¥4 O
on O
a O
0-10 O
scale O
or O
at O
least O
moderate O
functional O
impairment O
due O
to O
pain O
were O
randomly O
assigned O
to O
TEC O
or O
enhanced O
usual O
care O
( O
EUC O
) O
during O
a O
telephone O
interview O
conducted O
in O
advance O
of O
a O
planned O
oncology O
office O
visit O
( O
265 O
patients O
randomized O
to O
TEC O
or O
EUC O
";" O
258 O
completed O
at O
least O
one O
follow-up O
) O
. O

We O
based O
the O
program O
on O
the O
CRF O
guidelines O
of O
the O
National O
Comprehensive O
Cancer O
Network O
( O
NCCN O
) O
and O
incorporated O
the O
transtheoretic O
model O
( O
TTM O
) O
. O

To O
observe O
the O
effect O
of O
TCM O
therapy O
for O
removing O
toxic O
substance O
and O
unblocking O
meridians O
on O
post-radiation O
quality O
of O
life O
( O
QOF O
) O
in O
55 O
patients O
with O
lung O
cancer O
. O

Secondary O
endpoints O
included O
response O
rate O
( O
RR O
) O
, O
overall O
survival O
( O
OS O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

For O
the O
last O
six O
months O
, O
all O
received O
the O
1 O
+ O
2.5 O
dosage O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
";" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

We O
enrolled O
1669 O
eligible O
patients O
, O
382 O
( O
23 O
% O
) O
with O
ER-negative O
tumors O
, O
1217 O
( O
73 O
% O
) O
with O
ER-positive O
tumors O
, O
and O
70 O
( O
4 O
% O
) O
with O
unknown O
ER O
status O
. O

Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node-negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O

A O
consecutive O
subsample O
of O
patients O
was O
invited O
to O
complete O
the O
EQ-5D O
surveys O
. O

Analyses O
of O
covariance O
were O
used O
to O
study O
the O
long-term O
effectiveness O
of O
CBT O
. O

Exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O

To O
determine O
the O
effect O
of O
a O
nursing-led O
intervention O
on O
quality O
of O
life O
, O
symptom O
intensity O
, O
mood O
, O
and O
resource O
use O
in O
patients O
with O
advanced O
cancer O
. O

An O
understanding O
of O
the O
patterns O
of O
side-effects O
and O
time O
dimension O
of O
their O
occurrence O
for O
each O
treatment O
is O
important O
for O
full O
patient O
information O
. O

Sixty-one O
patients O
were O
enrolled O
from O
the O
Salt O
Lake O
City O
Veterans O
Affairs O
Hospital O
";" O
51 O
completed O
the O
study O
and O
were O
included O
in O
the O
analysis O
. O

The O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
CR/PR O
, O
SD O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
PD O
) O
. O

In O
this O
multicenter O
, O
open-label O
, O
randomized O
phase O
II O
trial O
, O
women O
with O
locally O
advanced O
or O
MBC O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
90 O
mg/m O
( O
2 O
) O
( O
days O
1 O
, O
8 O
, O
15 O
) O
and O
bevacizumab O
10 O
mg/kg O
( O
days O
1 O
, O
15 O
) O
with O
or O
without O
gemcitabine O
1500 O
mg/m O
( O
2 O
) O
( O
days O
1 O
, O
15 O
) O
in O
28-day O
cycles O
. O

The O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
KPS O
scores O
, O
QLQ-C30 O
questionnaire O
, O
LC13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
TCM O
efficacy O
, O
the O
6-min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

Double-blind O
, O
randomized O
clinical O
trial O
. O

Prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
";" O
mean O
age O
, O
55.2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
January O
2005 O
and O
January O
2008 O
. O

Using O
a O
two-group O
, O
randomized O
controlled O
design O
, O
we O
assigned O
76 O
postmenopausal O
breast O
cancer O
survivors O
with O
at O
least O
one O
severe O
target O
symptom O
either O
to O
the O
intervention O
group O
or O
to O
a O
usual-care O
group O
. O

Secondary O
outcome O
measures O
included O
treatment-associated O
morbidity O
, O
mortality O
, O
survival O
, O
and O
cost-effectiveness O
. O

There O
were O
fewer O
patients O
with O
a O
performance O
status O
of O
0 O
( O
n O
= O
11 O
v O
20 O
) O
, O
and O
fewer O
had O
CR O
to O
initial O
therapy O
( O
n O
= O
4 O
v O
8 O
) O
in O
the O
vandetanib O
arm O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

Stage O
IV O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1,600 O
mg/d O
of O
megestrol O
acetate O
. O

Caloric O
intake O
, O
body O
composition O
( O
dual-energy O
x-ray O
absorptiometry O
) O
, O
and O
respiratory O
gas O
exchanges O
at O
rest O
and O
during O
exercise O
were O
measured O
including O
health-related O
quality O
of O
life O
. O

After O
surgery O
for O
differentiated O
thyroid O
carcinoma O
, O
many O
patients O
are O
treated O
with O
radioiodine O
to O
ablate O
remnant O
thyroid O
tissue O
. O

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

A O
total O
of O
166 O
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
. O

Patients O
( O
n O
= O
829 O
) O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT-B+4 O
) O
and O
the O
Spielberger O
State/Trait O
Anxiety O
Inventory O
( O
STAI O
) O
at O
baseline O
( O
pre-surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post-surgery O
. O

Statistical O
tests O
were O
two-sided O
. O

Eighty-nine O
chemotherapy-naÃ¯ve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

Measures O
included O
psychological O
( O
distress O
) O
, O
biological O
( O
immune O
) O
, O
and O
health O
outcomes O
( O
performance O
status O
and O
evaluations O
of O
patient O
's O
symptomatology O
, O
including O
toxicity O
from O
cancer O
treatment O
, O
lab O
values O
) O
collected O
at O
baseline O
, O
4 O
months O
, O
and O
12 O
months O
. O

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1-those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2-those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3-those O
receiving O
bicalutamide O
and O
RT O
. O

Statistical O
significance O
was O
kept O
at O
p O
< O
0.05 O
. O

Supportive O
care O
included O
palliative O
radiotherapy O
and O
supportive O
therapy O
with O
corticosteroids O
, O
antibiotics O
, O
analgesics O
, O
antiemetics O
, O
transfusions O
, O
and O
other O
symptomatic O
therapy O
as O
required O
. O

The O
patients O
were O
randomized O
to O
either O
standard O
esophagectomy O
or O
definitive O
CRT O
. O

In O
the O
Asia-Pacific O
region O
and O
elsewhere O
, O
almost O
85 O
% O
of O
patients O
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
are O
inoperable O
at O
diagnosis O
and O
have O
a O
dismal O
prognosis O
. O

Based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J-pouch O
. O

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low-dose O
and O
high-dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

Median O
adherence O
to O
the O
supervised O
exercise O
program O
was O
92 O
% O
. O

Quality O
of O
life O
was O
assessed O
using O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
. O

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

However O
, O
few O
studies O
have O
investigated O
their O
effectiveness O
in O
patients O
who O
are O
receiving O
chemotherapy O
. O

Outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
QOL O
( O
Linear O
Analogue O
Self-Assessment O
( O
LASA O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
) O
and O
mood O
( O
Profile O
of O
Mood O
States O
( O
POMS O
) O
) O
. O

A O
median O
of O
four O
cycles O
was O
administered O
in O
each O
arm O
. O

Secondary O
end O
points O
were O
depressive O
symptoms O
and O
post-traumatic O
growth O
. O

Stratification O
factors O
included O
chemotherapy O
cycle O
length O
, O
screening O
hemoglobin O
( O
< O
10 O
g/dL O
vs. O
â‰¥10 O
g/dL O
) O
, O
and O
tumor O
type O
( O
lung/gynecological O
vs. O
other O
nonmyeloid O
malignancies O
) O
. O

Exclusion O
criteria O
included O
age O
greater O
than O
70 O
years O
, O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
greater O
than O
2 O
, O
prior O
chemotherapy O
for O
metastatic O
disease O
, O
and O
presence O
of O
liver O
metastases O
in O
patients O
younger O
than O
50 O
. O

Treatment O
duration O
was O
8 O
weeks O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

Thirty-nine O
patients O
were O
randomly O
assigned O
to O
CONNECT O
and O
36 O
to O
usual O
care O
. O

Additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
RR O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O

Advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1,000 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O

In O
this O
randomized O
phase O
III O
trial O
, O
a O
total O
of O
313 O
Korean O
never-smokers O
with O
stage O
IIIB O
or O
IV O
lung O
adenocarcinoma O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
0 O
to O
2 O
, O
and O
adequate O
organ O
function O
were O
randomly O
assigned O
to O
receive O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
GP O
chemotherapy O
( O
gemcitabine O
1,250 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
";" O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
, O
for O
up O
to O
nine O
courses O
) O
. O

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

Overall O
disease-related O
symptom O
improvement O
was O
assessed O
using O
an O
eight-item O
questionnaire O
. O

Self-report O
questionnaires O
were O
completed O
at O
baseline O
, O
12 O
weeks O
, O
and O
6 O
months O
. O

From O
May O
1999 O
to O
December O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
SLN O
biopsy O
associated O
with O
ALND O
( O
ALND O
arm O
) O
or O
SLN O
biopsy O
followed O
by O
ALND O
only O
if O
the O
SLN O
was O
metastatic O
( O
SLN O
arm O
) O
. O

The O
stretch O
group O
received O
instruction O
on O
low-load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

Between O
1990 O
and O
1997 O
, O
714 O
patients O
with O
stage O
IC O
grade O
1 O
to O
2 O
or O
IB O
grade O
2 O
to O
3 O
EC O
were O
randomly O
allocated O
to O
pelvic O
external-beam O
radiotherapy O
( O
EBRT O
) O
or O
no O
additional O
treatment O
( O
NAT O
) O
. O

To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
'low-risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0-2 O
) O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

Women O
( O
N=13388 O
) O
at O
increased O
risk O
for O
breast O
cancer O
because O
they O
1 O
) O
were O
60 O
years O
of O
age O
or O
older O
, O
2 O
) O
were O
35-59 O
years O
of O
age O
with O
a O
5-year O
predicted O
risk O
for O
breast O
cancer O
of O
at O
least O
1.66 O
% O
, O
or O
3 O
) O
had O
a O
history O
of O
lobular O
carcinoma O
in O
situ O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n=6707 O
) O
or O
20 O
mg/day O
tamoxifen O
( O
n=6681 O
) O
for O
5 O
years O
. O

Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index-Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

Between O
February O
1999 O
and O
August O
2001 O
, O
422 O
patients O
( O
GCa O
, O
n O
= O
212 O
";" O
MIC O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
United O
Kingdom O
. O

Primary O
end-point O
was O
overall O
response O
to O
first-line O
treatment O
among O
TS O
high O
patients O
. O

Patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O

This O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
Individual O
Internet O
Intervention O
( O
III O
) O
embedded O
and O
integrated O
into O
an O
Internet O
Support O
Group O
( O
ISG O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O

This O
trial O
was O
undertaken O
to O
determine O
whether O
adjuvant O
treatment O
with O
the O
metalloproteinase O
inhibitor O
marimastat O
could O
prolong O
survival O
in O
responding O
patients O
with O
SCLC O
after O
chemotherapy O
. O

From O
February O
2007 O
to O
July O
2008 O
, O
116 O
patients O
were O
enrolled O
and O
113 O
were O
included O
in O
the O
intent-to-treat O
population O
: O
57 O
patients O
in O
the O
E O
group O
and O
56 O
patients O
in O
the O
V O
group O
. O

On O
November O
18 O
, O
2004 O
, O
the O
FDA O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

A O
randomized O
controlled O
trial O
was O
conducted O
in O
cooperation O
with O
the O
Departments O
of O
General O
Surgery O
and O
Medical O
Psychology O
, O
University O
Hospital O
of O
Hamburg O
, O
Germany O
, O
from O
January O
1991 O
to O
January O
1993 O
. O

Safety O
and O
efficacy O
( O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
criteria O
responses O
, O
DAS28 O
( O
C-reactive O
protein O
) O
, O
HAQ-DI O
, O
SF-36 O
, O
Medical O
Outcomes O
Study O
Sleep O
Problems O
Index O
, O
fatigue O
VAS O
) O
were O
assessed O
through O
2 O
years O
. O

Two O
university O
hospitals O
in O
Copenhagen O
, O
Denmark O
. O

Many O
patients O
with O
cancer O
experience O
depression O
and O
anxiety O
, O
and O
an O
associated O
decrease O
in O
quality O
of O
life O
( O
QOL O
) O
during O
radiation O
therapy O
( O
RT O
) O
. O

One O
hundred O
forty O
consecutive O
patients O
with O
pilonidal O
sinus O
were O
randomly O
assigned O
to O
receive O
either O
UM O
or O
RELP O
procedures O
. O

The O
primary O
end-point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Dosing O
was O
reduced O
to O
25 O
mg/d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3/4 O
AEs O
. O

Results O
indicate O
no O
significant O
differences O
between O
groups O
for O
length O
of O
stay O
( O
t O
= O
.97 O
, O
df O
= O
25 O
, O
p O
> O
.05 O
) O
. O

186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

Discussion O
topics O
were O
predominantly O
raised O
by O
patients/relatives O
, O
regardless O
of O
arm O
allocation O
. O

The O
trial O
was O
closed O
because O
it O
had O
ruled O
out O
a O
significant O
benefit O
of O
sertraline O
. O

Primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
end O
points O
included O
overall O
response O
rate O
( O
ORR O
) O
and O
progression-free O
survival O
( O
PFS O
) O
. O

Patients O
with O
hormone-refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double-blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
N O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
";" O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
or O
placebo O
( O
N O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O

They O
were O
stratified O
by O
sex O
, O
age O
, O
institute O
, O
histology O
, O
and O
degree O
of O
lymph O
node O
dissection O
. O

The O
primary O
outcome O
was O
QOL O
. O

Forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O

The O
recommended O
regimens O
were O
17 O
Gy O
in O
two O
fractions O
one O
week O
apart O
or O
10 O
Gy O
as O
a O
single O
dose O
. O

Dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90-99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O

Outcomes O
included O
quality O
of O
life O
( O
QoL O
) O
, O
function O
( O
fitness O
and O
upper O
body O
) O
and O
treatment-related O
side O
effects O
( O
fatigue O
, O
lymphoedema O
, O
body O
mass O
index O
, O
menopausal O
symptoms O
, O
anxiety O
, O
depression O
and O
pain O
) O
. O

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

We O
report O
the O
QOL O
results O
of O
JBR.10 O
, O
a O
North O
American O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
IB O
to O
II O
NSCLC O
. O

Significance O
testing O
of O
group-by-time O
interactions O
in O
286 O
patients O
who O
completed O
all O
assessments O
was O
used O
to O
evaluate O
intervention O
efficacy O
. O

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

Thirty-six O
women O
with O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

SATURN O
( O
Sequential O
Tarceva O
in O
Unresectable O
NSCLC O
) O
was O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
, O
multicentre O
study O
investigating O
the O
impact O
of O
erlotinib O
maintenance O
therapy O
on O
HRQoL O
in O
patients O
with O
locally O
advanced O
or O
recurrent O
NSCLC O
. O

Time O
points O
were O
: O
baseline O
( O
prior O
to O
randomization O
) O
and O
prior O
to O
chemotherapy O
cycles O
2 O
, O
3 O
, O
and O
4 O
. O

Eligible O
patients O
who O
had O
previously O
completed O
four O
cycles O
of O
platinum-based O
chemotherapy O
were O
randomised O
1:1 O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
death O
. O

The O
aim O
of O
this O
study O
is O
to O
explore O
the O
effects O
, O
safety O
, O
and O
quality O
of O
life O
( O
QoL O
) O
of O
Gefitinib O
and O
Pemetrexed O
on O
patients O
with O
advanced O
non-squamous O
NSCLC O
. O

Patients O
aged O
18-75 O
years O
with O
resectable O
cancer O
of O
the O
oesophagus O
or O
gastro-oesophageal O
junction O
were O
randomly O
assigned O
via O
a O
computer-generated O
randomisation O
sequence O
to O
receive O
either O
open O
transthoracic O
or O
minimally O
invasive O
transthoracic O
oesophagectomy O
. O

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

Therapeutic O
protocols O
associated O
with O
appropriate O
and O
effective O
psychological O
and O
social O
support O
systems O
are O
essential O
to O
counteract O
the O
symptoms O
of O
neoplastic O
disease O
in O
incurable O
patients O
. O

Two O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
One O
patient O
suspended O
ghrelin O
administration O
because O
of O
excessive O
diaphoresis O
, O
and O
another O
patient O
in O
the O
placebo O
group O
failed O
to O
monitor O
the O
self-questionnaire O
. O

Interim O
analysis O
halfway O
through O
the O
trial O
had O
a O
Lan-DeMets O
monitoring O
boundary O
with O
an O
O'Brien-Fleming O
stopping O
rule O
. O

At O
the O
last O
follow-up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

To O
determine O
the O
efficacy O
and O
safety O
of O
a O
biweekly O
regimen O
of O
leucovorin O
( O
LV O
) O
plus O
fluorouracil O
( O
FU O
) O
alone O
or O
in O
combination O
with O
cisplatin O
or O
irinotecan O
in O
patients O
with O
previously O
untreated O
metastatic O
gastric O
adenocarcinoma O
and O
to O
select O
the O
best O
arm O
for O
a O
phase O
III O
study O
. O

Of O
87 O
eligible O
patients O
, O
75 O
consented O
( O
86 O
% O
consent O
rate O
) O
. O

We O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel/bevacizumab O
( O
PB O
) O
. O

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

Evaluation O
at O
baseline O
, O
after O
8 O
sessions O
, O
and O
1 O
month O
after O
programme O
completion O
, O
included O
evaluations O
using O
the O
STAI O
, O
POMS O
, O
MAC O
, O
EORTC O
QLQ-C30 O
and O
EORTC O
QLQ-BR23 O
breast O
module O
scales O
. O

After O
removing O
patients O
who O
did O
not O
complete O
the O
follow-up O
survey O
or O
censured O
cases O
, O
24 O
patients O
in O
the O
RY O
group O
and O
18 O
patients O
in O
the O
INT O
group O
were O
clinically O
available O
and O
their O
postoperative O
status O
was O
assessed O
. O

In O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O

Seventy-five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM-treated O
patients O
versus O
PLD-treated O
patients O
( O
P O
= O
.007 O
) O
. O

QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
a O
trial-specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow-up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

One O
hundred O
twenty-eight O
of O
177 O
eligible O
patients O
of O
a O
randomized O
trial O
( O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
20/90 O
) O
receiving O
either O
formestane O
( O
250 O
mg O
intramuscularly O
biweekly O
) O
or O
megestrol O
acetate O
( O
160 O
mg O
orally O
daily O
) O
were O
analyzed O
. O

To O
prospectively O
evaluate O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
outcomes O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
and O
hysterectomy O
up O
to O
24 O
months O
after O
the O
intervention O
in O
terms O
of O
mental O
and O
physical O
health O
, O
urinary O
and O
defecatory O
function O
, O
and O
overall O
patient O
satisfaction O
. O

One O
hundred O
ninety O
patients O
with O
extremity O
STS O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O

The O
aim O
of O
the O
project O
was O
to O
identify O
clinical O
and O
quality O
of O
life O
( O
QL O
) O
factors O
that O
together O
predict O
survival O
and O
response O
to O
chemotherapy O
in O
advanced O
breast O
cancer O
. O

The O
final O
analysis O
was O
conducted O
as O
planned O
after O
256 O
progression O
events O
( O
median O
follow-up O
, O
20.5 O
months O
) O
. O

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

Intensity O
of O
service O
was O
measured O
as O
the O
number O
of O
days O
in O
the O
hospital O
and O
in O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
the O
number O
of O
emergency O
department O
visits O
recorded O
in O
the O
electronic O
medical O
record O
. O

End O
points O
were O
the O
rate O
of O
success O
of O
ablation O
at O
6 O
to O
9 O
months O
, O
adverse O
events O
, O
quality O
of O
life O
, O
and O
length O
of O
hospital O
stay O
. O

SCLC O
patients O
in O
complete O
or O
partial O
remission O
were O
eligible O
. O

At O
baseline O
, O
no O
significant O
difference O
was O
observed O
among O
the O
three O
groups O
. O

The O
brief O
period O
of O
poorer O
QoL O
with O
standard O
treatment O
is O
a O
modest O
price O
to O
pay O
for O
a O
chance O
at O
improved O
survival O
. O

Sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
";" O
age O
61.9+/-14 O
years O
[ O
mean+/-standard O
deviation O
] O
) O
. O

Efficacy O
of O
RT O
based O
on O
clinical O
, O
radiologic O
, O
and O
prostate-specific O
antigen O
data O
were O
also O
evaluated O
at O
baseline O
and O
after O
RT O
. O

A O
multicenter O
trial O
was O
conducted O
to O
determine O
the O
efficacy O
and O
toxicity O
of O
escalating O
dosages O
of O
liposomal O
tretinoin O
( O
all-trans-retinoic O
acid O
) O
administered O
once O
or O
three O
times O
weekly O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

Seventy-five O
patients O
with O
head O
and O
neck O
cancer O
who O
were O
referred O
for O
radiotherapy O
( O
RT O
) O
were O
randomized O
to O
the O
following O
groups O
: O
group O
1 O
( O
n O
= O
25 O
) O
, O
patients O
who O
received O
dietary O
counseling O
with O
regular O
foods O
";" O
group O
2 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
usual O
diet O
plus O
supplements O
";" O
and O
group O
3 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
intake O
ad O
lib O
. O

Pleural O
fluid O
was O
collected O
from O
both O
groups O
prior O
to O
and O
following O
treatment O
. O

A O
total O
of O
798 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stage O
IIB-IV O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
PT O
or O
TC O
at O
3-week O
intervals O
. O

Patients O
completed O
measures O
assessing O
pain O
, O
psychological O
distress O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
self-efficacy O
for O
symptom O
management O
";" O
caregivers O
completed O
measures O
assessing O
psychological O
distress O
, O
caregiver O
strain O
, O
and O
self-efficacy O
for O
helping O
the O
patient O
manage O
symptoms O
. O

A O
non-randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

The O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
RR O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
RR O
with O
the O
standard O
treatment O
if O
the O
TRUE O
difference O
is O
15 O
% O
or O
more O
. O

Asymptomatic O
postmenopausal O
women O
who O
took O
adjuvant O
tamoxifen O
for O
2 O
to O
3 O
years O
for O
operable O
breast O
cancer O
with O
a O
double O
endometrial O
thickness O
greater O
than O
7 O
mm O
were O
randomized O
to O
20 O
mg O
tamoxifen O
or O
1 O
mg O
anastrozole O
for O
the O
remaining O
duration O
, O
totaling O
5 O
years O
. O

This O
pilot O
trial O
assessed O
the O
feasibility O
of O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
comparing O
epidural O
analgesia O
and O
use O
of O
a O
local O
anaesthetic O
wound O
infusion O
catheter O
( O
WIC O
) O
following O
LCR O
. O

Multiple O
measures O
were O
used O
for O
corroboration O
of O
the O
most O
important O
outcomes O
. O

Study O
follow-up O
was O
completed O
July O
2012 O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

Missing O
data O
at O
baseline O
and O
during O
follow-up O
was O
equally O
distributed O
between O
groups O
. O

The O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
ARSR O
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group/The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG/EORTC O
scale O
) O
at O
follow-up O
. O

Patients O
' O
quality O
of O
life O
was O
evaluated O
with O
the O
Cardiff O
Wound O
Impact O
Schedule O
( O
CWIS O
) O
. O

The O
8-week O
programme O
of O
2 O
h O
sessions O
comprised O
of O
thematic O
discussions O
, O
information O
and O
training O
in O
stress O
management O
techniques O
. O

Survival O
differences O
were O
analyzed O
by O
Wilcoxon O
and O
log-rank O
tests O
. O

Immunobiological O
cancer O
therapy O
plays O
an O
important O
role O
in O
strengthening O
body O
immunological O
surveillance O
function O
and O
killing O
remaining O
tumor O
cells O
in O
the O
body O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

The O
median O
age O
of O
patients O
was O
70 O
years O
. O

However O
, O
the O
survival O
and O
quality-of-life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

Subjects O
( O
N O
= O
27 O
) O
were O
patients O
admitted O
for O
some O
type O
of O
surgical O
procedure O
of O
the O
brain O
. O

Cancer O
cachexia O
is O
a O
common O
problem O
among O
advanced O
cancer O
patients O
. O

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

Hospital O
anxiety O
and O
depression O
scale O
scores O
were O
consistent O
with O
the O
primary O
outcome O
measure O
. O

The O
Medical O
Outcomes O
Trust O
Short-Form O
36 O
Survey O
was O
used O
to O
measure O
quality O
of O
life O
before O
and O
after O
the O
intervention O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

Endpoints O
included O
the O
QLQ-C30 O
Global O
Health O
Status O
( O
QL2 O
) O
scale O
, O
the O
QLQ-BR23 O
breast O
symptom O
( O
BRBS O
) O
, O
and O
arm O
symptom O
( O
BRAS O
) O
scales O
. O

To O
analyze O
and O
compare O
radiologic O
lung O
expansion O
after O
talc O
pleurodesis O
performed O
either O
by O
videothoracoscopy O
or O
chest O
tube O
and O
correlate O
it O
with O
clinical O
outcome O
. O

The O
median O
number O
of O
cycles O
administered O
was O
two O
in O
both O
arms O
( O
range O
0-14 O
) O
. O

Stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O

Median O
ECOG O
was O
1 O
, O
and O
median O
number O
of O
prior O
chemotherapy O
regimens O
was O
2 O
. O

End O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
and O
response O
duration O
( O
RD O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
OS O
) O
. O

Thus O
, O
300 O
patients O
were O
assessable O
for O
toxicity O
and O
to O
determine O
time O
to O
disease O
progression O
( O
TTP O
) O
, O
TTF O
, O
and O
OS O
. O

The O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O

A O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

One O
hundred O
patients O
with O
mild-moderate O
pain O
were O
randomized O
to O
treatment O
according O
to O
WHO O
guidelines O
or O
to O
treatment O
with O
strong O
opioids O
. O

At O
disease O
progression O
, O
temozolomide O
salvage O
treatment O
was O
given O
to O
161 O
of O
282 O
patients O
( O
57 O
% O
) O
in O
the O
radiotherapy O
alone O
arm O
, O
and O
to O
62 O
of O
277 O
patients O
( O
22 O
% O
) O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effectiveness O
of O
a O
pain O
management O
program O
( O
PMP O
) O
on O
pain O
intensity O
, O
use O
of O
PRN O
drugs O
and O
nonpharmacological O
strategies O
as O
pain O
relief O
, O
and O
barriers O
to O
managing O
pain O
in O
cancer O
patients O
. O

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

Sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O

Approximately O
38 O
% O
of O
patients O
who O
received O
zoledronic O
acid O
at O
4 O
mg O
, O
28 O
% O
who O
received O
zoledronic O
acid O
at O
8/4 O
mg O
, O
and O
31 O
% O
who O
received O
placebo O
completed O
the O
study O
. O

Two O
hundred O
forty-six O
of O
302 O
patients O
randomly O
assigned O
provided O
complete O
data O
at O
6 O
weeks O
. O

Functional O
assessment O
of O
cancer O
therapy O
( O
FACT O
) O
questionnaire O
, O
Beck O
depression O
inventory O
, O
positive O
and O
negative O
affect O
scale O
, O
body O
mass O
index O
, O
seven O
day O
recall O
of O
physical O
activity O
, O
12 O
minute O
walk O
test O
, O
and O
assessment O
of O
shoulder O
mobility O
. O

Fourteen O
breast O
cancer O
survivors O
with O
unilateral O
upper O
extremity O
lymphedema O
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
7 O
) O
or O
control O
group O
( O
n O
= O
7 O
) O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

QOL O
information O
, O
using O
validated O
instruments O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
[ O
FACT-L O
] O
, O
version O
2 O
, O
and O
Functional O
Living O
Index-Cancer O
[ O
FLIC O
] O
) O
, O
was O
prospectively O
collected O
in O
patients O
with O
locally O
advanced O
NSCLC O
treated O
on O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
trial O
89-01 O
. O

Quality O
of O
life O
was O
determined O
at O
the O
time O
of O
randomization O
and O
ablation O
. O

Patients O
with O
previously O
untreated O
histologically O
or O
cytologically O
proven O
locally O
advanced O
or O
metastatic O
carcinoma O
of O
the O
pancreas O
with O
a O
performance O
status O
< O
or= O
2 O
were O
recruited O
. O

The O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short-term O
efficacy O
, O
TCM O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

Patients O
were O
randomly O
assigned O
to O
sequential O
doxorubicin O
( O
A O
) O
and O
cyclophosphamide O
( O
C O
) O
followed O
by O
docetaxel O
( O
T O
";" O
ACâ†’T O
) O
, O
concurrent O
TAC O
, O
or O
AT O
, O
which O
varied O
in O
duration O
( O
24 O
, O
12 O
, O
12 O
weeks O
, O
respectively O
) O
, O
and O
use O
of O
C. O
Endocrine O
therapy O
was O
prescribed O
for O
women O
with O
hormone O
receptor-positive O
tumors O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF O
level O
. O

Mucositis O
was O
scored O
using O
a O
validated O
mucositis O
scoring O
system O
. O

This O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O

Bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O

Prospective O
outcomes O
included O
patient-reported O
symptoms O
and O
quality O
of O
life O
assessed O
with O
questionnaires O
from O
baseline O
to O
4 O
years O
after O
randomisation O
. O

Patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13-CRA O
1 O
mg/kg/d O
plus O
IFNalpha2a O
. O

Within O
the O
FLOT65+ O
trial O
, O
a O
total O
of O
143 O
patients O
aged O
â‰¥65 O
years O
were O
randomly O
allocated O
to O
receive O
biweekly O
oxaliplatin O
plus O
5-fluorouracil O
( O
5-FU O
) O
continuous O
infusion O
and O
folinic O
acid O
( O
FLO O
) O
or O
the O
same O
regimen O
in O
combination O
with O
docetaxel O
50 O
mg/m O
( O
2 O
) O
( O
FLOT O
) O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

There O
were O
38 O
hospitalized O
patients O
, O
with O
20 O
( O
13 O
males O
and O
7 O
females O
) O
in O
the O
experimental O
group O
and O
18 O
( O
11 O
males O
and O
7 O
females O
) O
in O
the O
control O
group O
";" O
mean O
age O
was O
61.95 O
years O
( O
experimental O
group O
) O
to O
63.94 O
years O
( O
control O
group O
) O
. O

Before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
VO2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit-stand O
test O
. O

Few O
exercise O
trials O
in O
cancer O
patients O
have O
reported O
longer-term O
follow-up O
. O

We O
assessed O
whether O
such O
patients O
could O
be O
helped O
if O
a O
practitioner O
followed O
an O
investigative O
and O
management O
algorithm O
, O
and O
whether O
outcomes O
differed O
by O
whether O
a O
nurse O
or O
a O
gastroenterologist O
led O
this O
algorithm-based O
care O
. O

We O
recruited O
273 O
participants O
and O
randomly O
assigned O
136 O
to O
the O
intervention O
group O
. O

or O
12 O
months O
( O
p.o O
. O
) O
. O

Evidence O
that O
community O
cancer O
services O
improve O
care O
quality O
and/or O
generate O
cost O
savings O
is O
currently O
limited O
. O

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

Using O
KPS O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O

Our O
purpose O
was O
to O
assess O
the O
impact O
of O
cisplatin O
( O
C O
) O
versus O
cisplatin O
plus O
paclitaxel O
( O
CP O
) O
on O
overall O
QOL O
and O
pain O
in O
cervical O
cancer O
patients O
. O

Manual O
lymphatic O
drainage O
( O
MLD O
) O
and O
compression O
bandage O
combination O
( O
complex O
decongestive O
therapy O
) O
have O
been O
compared O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
plus O
self-lymphatic O
drainage O
( O
SLD O
) O
. O

Using O
a O
single-blinded O
, O
3-armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral-sparing O
techniques O
( O
100-150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c-T2c O
prostate O
cancer O
. O

Despite O
this O
, O
it O
remains O
an O
understudied O
, O
underreported O
, O
and O
undertreated O
issue O
in O
the O
field O
of O
cancer O
survivorship O
. O

In O
nonrandomized O
trials O
, O
doses O
studied O
have O
ranged O
from O
135 O
mg/m2 O
to O
250 O
mg/m2 O
administered O
over O
24 O
hours O
with O
premedication O
to O
avoid O
hypersensitivity O
reactions O
( O
HSRs O
) O
. O

Supervised O
exercise O
comprising O
high O
intensity O
cardiovascular O
and O
resistance O
training O
, O
relaxation O
and O
body O
awareness O
training O
, O
massage O
, O
nine O
hours O
weekly O
for O
six O
weeks O
in O
addition O
to O
conventional O
care O
, O
compared O
with O
conventional O
care O
. O

What O
's O
known O
on O
the O
subject O
? O

The O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
RP O
) O
plus O
observation O
versus O
RP O
plus O
adjuvant O
radiation O
therapy O
( O
RT O
) O
. O

These O
patients O
experience O
significant O
functional O
impairment O
and O
muscle O
atrophy O
, O
which O
may O
lead O
to O
an O
increased O
likelihood O
of O
skeletal O
complicaTIOns O
( O
i.e. O
, O
pathological O
fracture O
, O
bone O
pain O
) O
and/or O
falls O
. O

Before O
the O
knowledge O
that O
5 O
years O
of O
adjuvant O
tamoxifen O
is O
less O
efficacious O
than O
2 O
to O
3 O
years O
of O
tamoxifen O
followed O
by O
2 O
to O
3 O
years O
of O
anastrozole/exemestane O
, O
we O
designed O
a O
multicenter O
double-blind O
randomized O
controlled O
trial O
in O
women O
taking O
tamoxifen O
with O
a O
thickened O
endometrium O
to O
compare O
uterine O
and O
quality-of-life O
parameters O
between O
those O
switching O
to O
anastrozole O
and O
those O
continuing O
tamoxifen O
. O

Endpoints O
included O
MD O
Anderson O
Symptom O
Inventory-Head O
and O
Neck O
( O
MDASI-HN O
) O
and O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-NH O
) O
scores O
, O
along O
with O
clinical O
assessment O
and O
DNA O
concentration O
of O
OPS O
. O

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

and O
intravenous O
( O
i.v O
. O
) O

Grade O
3 O
or O
4 O
palmar-plantar O
erythrodysesthesia O
was O
documented O
in O
a O
higher O
proportion O
of O
PLD O
patients O
( O
6 O
% O
) O
versus O
GEM O
patients O
( O
0 O
% O
";" O
P O
= O
.061 O
) O
. O

After O
treatment O
arm O
was O
controlled O
for O
, O
MSTS O
change O
scores O
were O
predicted O
by O
a O
lower-extremity O
tumor O
, O
a O
large O
resection O
specimen O
, O
and O
motor O
nerve O
sacrifice O
";" O
TESS O
change O
scores O
were O
predicted O
by O
lower-extremity O
tumor O
and O
prior O
incomplete O
excision O
. O

Fifty O
GI O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
TPN O
after O
operation O
. O

RECIST-defined O
objective O
response O
rate O
( O
ORR O
) O
was O
the O
primary O
end O
point O
. O

Median O
age O
was O
76 O
years O
( O
range O
, O
70 O
years O
to O
86 O
years O
) O
. O

Results O
Baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

Patients O
receiving O
DPPE O
were O
aggressively O
premedicated O
to O
ameliorate O
toxicity O
. O

The O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22-87 O
) O
. O

Worsening O
of O
symptoms O
was O
defined O
as O
an O
increase O
of O
15 O
mm O
or O
more O
from O
baseline O
on O
a O
100 O
mm O
scale O
for O
each O
LCSS O
item O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

Kaposi O
's O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
Zimbabwe O
. O

The O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O

Patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
screened O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

We O
compared O
the O
combination O
of O
docetaxel-carboplatin O
with O
the O
combination O
of O
paclitaxel-carboplatin O
as O
first-line O
chemotherapy O
for O
stage O
Ic-IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

HEC O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O

All O
patients O
who O
returned O
questionnaires O
at O
12 O
months O
and O
were O
still O
on O
study O
treatment O
were O
included O
in O
the O
analysis O
of O
the O
primary O
endpoint O
. O

Patients O
received O
either O
r-HuEPO O
( O
150 O
U/kg O
) O
or O
placebo O
, O
subcutaneously O
, O
three O
times O
a O
week O
for O
3 O
months O
. O

Misoprostol O
is O
a O
synthetic O
prostaglandin O
E1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O

Most O
effects O
were O
found O
at O
3 O
months O
only O
. O

Data O
collection O
occurred O
at O
baseline O
before O
randomization O
and O
at O
4 O
months O
, O
8 O
months O
, O
and O
12 O
months O
. O

There O
were O
6 O
partial O
responses O
( O
18.2 O
% O
) O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
+/- O
13.2 O
) O
in O
Study O
A O
and O
7 O
partial O
responses O
( O
21.9 O
% O
) O
( O
95 O
% O
CI O
+/- O
14.3 O
) O
in O
Study O
B O
. O

Body O
plethysmography O
was O
used O
when O
available O
. O

Patients O
achieving O
complete O
remission O
with O
chemotherapy O
alone O
did O
not O
usually O
receive O
radiotherapy O
or O
undergo O
extensive O
surgery O
, O
but O
patients O
remaining O
in O
partial O
remission O
received O
local O
therapy O
with O
surgery O
and/or O
radiotherapy O
. O

This O
study O
investigated O
differences O
between O
the O
symptoms O
associated O
with O
either O
adjuvant O
tamoxifen O
or O
exemestane O
. O

Regimen O
A O
consisted O
of O
PAV O
( O
cisPlatin O
, O
Adriamycin O
, O
VP O
16-213 O
, O
and O
Regimen O
B O
of O
CyMOC O
( O
Cyclophosphamide O
, O
Methotrexate O
, O
Oncovin O
, O
CCNU O
) O
. O

QOL O
was O
assessed O
at O
baseline O
and O
week O
12 O
. O

Forty O
patients O
on O
Arm O
A O
and O
19 O
on O
Arm O
B O
received O
at O
least O
one O
treatment O
. O

To O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
NSCLC O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O

Doses O
for O
patients O
aged O
more O
than O
65 O
years O
were O
15 O
mg O
( O
first O
3 O
days O
) O
and O
30 O
mg O
( O
3 O
days O
after O
) O
. O

A O
total O
of O
314 O
patients O
were O
included O
in O
the O
clinical O
trial O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
. O

Training O
efficacy O
was O
not O
modified O
by O
patient O
characteristics O
. O

This O
double-blind O
randomized O
phase O
II O
trial O
examined O
whether O
vandetanib O
, O
an O
inhibitor O
of O
vascular O
endothelial O
and O
epidermal O
growth O
factor O
receptors O
, O
could O
prolong O
progression-free O
survival O
in O
responding O
patients O
with O
small-cell O
lung O
cancer O
. O

The O
predefined O
primary O
criterion O
for O
successful O
ablation O
was O
" O
no O
visible O
uptake O
in O
the O
thyroid O
bed O
, O
or O
if O
visible O
, O
fractional O
uptake O
less O
than O
0.1 O
% O
" O
on O
neck O
scans O
performed O
8 O
months O
after O
therapy O
and O
was O
satisfied O
in O
100 O
% O
of O
patients O
in O
both O
groups O
. O

In O
both O
groups O
, O
partners O
completed O
behavioral O
homework O
. O

Patients O
completing O
the O
6-month O
, O
double-blind O
period O
were O
eligible O
to O
enter O
the O
long-term O
extension O
";" O
patients O
received O
abatacept O
approximately O
10 O
mg/kg O
, O
plus O
disease-modifying O
antirheumatic O
drugs O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness-based O
art O
therapy O
( O
MBAT O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O

Anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self-report O
Visual O
Analog O
Scale O
( O
VAS O
) O
for O
each O
of O
the O
variables O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

Seventy-two O
patients O
who O
underwent O
surgery O
for O
lung O
( O
n=27 O
) O
or O
gastrointestinal O
tumours O
( O
n=42 O
) O
were O
assigned O
to O
an O
aerobic O
exercise O
group O
( O
stationary O
biking O
30 O
min O
five O
times O
weekly O
) O
or O
a O
progressive O
relaxation O
training O
group O
( O
45 O
min O
three O
times O
per O
week O
) O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

Exercise O
training O
improves O
supportive O
care O
outcomes O
in O
patients O
with O
breast O
cancer O
who O
are O
receiving O
adjuvant O
therapy O
, O
but O
the O
responses O
are O
heterogeneous O
. O

The O
statistical O
calculations O
were O
done O
as O
an O
exploratory O
data O
analysis O
. O

Allocation O
concealment O
was O
by O
use O
of O
opaque O
sealed O
envelopes O
. O

Cost-benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O

Median O
age O
was O
47 O
years O
( O
range O
, O
25 O
to O
67 O
years O
) O
. O

Improvement O
in O
PCS O
score O
at O
24-month O
follow-up O
was O
significantly O
higher O
for O
patients O
who O
were O
employed O
at O
baseline O
( O
P O
= O
.035 O
) O
. O

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

We O
did O
a O
multicentre O
, O
open-label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
June O
1 O
, O
2009 O
, O
and O
March O
31 O
, O
2011 O
. O

In O
phase O
II O
studies O
, O
irinotecan O
is O
active O
in O
metastatic O
colorectal O
cancer O
, O
but O
the O
overall O
benefit O
has O
not O
been O
assessed O
in O
a O
randomised O
clinical O
trial O
. O

One O
thousand O
eighty-eight O
women O
were O
randomly O
allocated O
to O
sentinel-lymph-node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
SNBM O
) O
or O
routine O
axillary O
clearance O
( O
RAC O
, O
sentinel-lymph-node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1-year O
follow-up O
( O
T3 O
) O
. O

To O
determine O
whether O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
on O
the O
well-being O
of O
patients O
with O
advanced O
cancer O
is O
more O
efficient O
when O
performed O
by O
a O
person O
with O
self-declared O
" O
healing O
powers O
" O
as O
compared O
to O
an O
actor O
mimicking O
the O
healer O
in O
close O
detail O
. O

Two O
hundred O
and O
three O
patients O
, O
recruited O
after O
primary O
treatment O
, O
were O
randomly O
assigned O
either O
to O
a O
treatment O
group O
( O
psycho-educational O
intervention O
) O
or O
to O
a O
waiting-list O
control O
group O
. O

A O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
QOL O
assessments O
. O

Kruskall-Wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

A O
small O
number O
of O
randomized O
controlled O
trials O
have O
examined O
the O
efficacy O
of O
antidepressants O
compared O
to O
that O
of O
a O
placebo O
in O
cancer O
patients O
, O
but O
some O
results O
have O
been O
difficult O
to O
interpret O
due O
to O
a O
heterogeneous O
patient O
group O
. O

In O
this O
international O
, O
6-month O
, O
open-label O
trial O
, O
patients O
had O
active O
RA O
, O
an O
inadequate O
response O
to O
anti-TNF O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
DAS28 O
( O
C-reactive O
protein O
";" O
CRP O
) O
of O
5.1 O
or O
greater O
. O

For O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O

There O
are O
few O
randomized O
controlled O
trials O
on O
the O
effectiveness O
of O
palliative O
care O
interventions O
to O
improve O
the O
care O
of O
patients O
with O
advanced O
cancer O
. O

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12-20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer-generated O
sequence O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

Future O
trials O
should O
be O
designed O
so O
that O
the O
CR/PR O
and O
SD O
( O
6m O
) O
groups O
are O
investigated O
separately O
. O

QOL O
was O
assessed O
over O
a O
1-year O
follow-up O
period O
, O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C-30 O
. O

The O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

Pretreatment O
characteristics O
were O
evenly O
distributed O
between O
the O
two O
arms O
. O

If O
CA125 O
concentration O
exceeded O
twice O
the O
upper O
limit O
of O
normal O
, O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
minimisation O
to O
early O
or O
delayed O
chemotherapy O
. O

Two O
primary O
end O
points O
were O
examined O
: O
energy/fatigue O
and O
cancer-specific O
distress O
. O

Gastrointestinal O
( O
GI O
) O
and O
genitourinary O
( O
GU O
) O
toxicity O
was O
evaluated O
before O
RT O
and O
after O
its O
completion O
using O
modified O
late O
effects O
of O
normal O
tissue-subjective O
, O
objective O
, O
management O
, O
analytic O
( O
LENT-SOMA O
) O
scales O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
sexual O
function O
questionnaire O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40,000 O
U O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

Primary O
outcome O
was O
general O
fatigue O
at O
6 O
weeks O
, O
measured O
with O
the O
Multidimensional O
Fatigue O
Inventory O
( O
MFI O
) O
. O

Proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

Costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
IV O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

The O
importance O
of O
parallel O
evaluation O
of O
survival O
and O
quality O
of O
life O
( O
QoL O
) O
has O
been O
recognized O
as O
fundamental O
and O
the O
aim O
was O
to O
assess O
QoL O
and O
quality O
adjusted O
survival O
. O

After O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
FJD O
. O

Mixed O
effects O
regressions O
were O
used O
to O
evaluate O
the O
intervention O
adjusting O
for O
patient O
, O
practice O
, O
and O
site O
characteristics O
. O

We O
report O
results O
of O
a O
randomized O
prospective O
study O
that O
compared O
single O
agents O
of O
low O
toxicity O
given O
both O
as O
the O
first-line O
and O
second-line O
chemotherapy O
with O
combination O
chemotherapy O
in O
advanced O
breast O
cancer O
with O
distant O
metastases O
. O

However O
, O
few O
studies O
have O
assessed O
whether O
changes O
in O
depression O
symptoms O
are O
associated O
with O
survival O
. O

A O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti-aromatase O
therapy O
( O
exemestane O
) O
and O
COX-2 O
inhibitors O
neoadjuvantly O
. O

Clinical O
follow-up O
was O
obtained O
in O
35 O
patients O
. O

Seventy O
patients O
completed O
the O
4 O
weeks O
period O
of O
study O
. O

Patient O
evaluation O
items O
included O
physical O
therapy O
assessment O
, O
limb O
size O
, O
water O
composition O
of O
the O
upper O
extremity O
, O
lymphedema-related O
symptoms O
, O
quality O
of O
life O
, O
and O
patients O
' O
acceptance O
to O
the O
bandage O
or O
tape O
. O

This O
triple O
blinded O
study O
randomized O
220 O
HNC O
patients O
scheduled O
for O
CRT O
( O
three O
weekly O
Cisplatin O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy/session O
) O
, O
five O
fractions/week O
for O
6.5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O

HRQL O
primary O
end O
points O
assessed O
by O
the O
EORTC O
QLQ-C30 O
were O
physical O
function O
( O
PF O
) O
and O
global O
health O
status O
( O
GHS O
) O
";" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O

From O
June O
2003 O
to O
December O
2003 O
, O
the O
10-year O
follow-up O
was O
conducted O
. O

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

The O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
WHO O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

GE O
responses O
: O
1 O
complete O
response O
( O
CR O
, O
1.2 O
% O
) O
, O
6 O
partial O
response O
( O
PR O
, O
7.4 O
% O
) O
, O
and O
33 O
stable O
disease O
( O
SD O
, O
40.7 O
% O
) O
";" O
disease O
control O
rate O
( O
DCR=CR+PR+SD O
, O
49.4 O
% O
) O
. O

Endpoints O
were O
overall O
survival O
, O
progression-free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

Patients O
( O
N O
= O
572 O
) O
with O
pretreated O
EGFR-detectable O
advanced O
CRC O
were O
randomly O
assigned O
to O
cetuximab O
and O
best O
supportive O
care O
( O
BSC O
) O
or O
to O
BSC O
alone O
. O

A O
randomised O
study O
was O
undertaken O
to O
compare O
delivery O
of O
cancer O
treatment O
in O
the O
hospital O
with O
two O
different O
community O
settings O
. O

This O
is O
, O
in O
part O
, O
because O
scales O
and O
measures O
of O
QOL O
are O
still O
relatively O
unfamiliar O
to O
most O
clinicians O
and O
because O
population-based O
reference O
ranges O
are O
lacking O
, O
thus O
making O
clinical O
trial O
results O
difficult O
to O
interpret O
. O

The O
first O
group O
received O
intrapleural O
bevacizumab O
( O
300 O
mg O
) O
with O
cisplatin O
( O
30 O
mg O
) O
therapy O
and O
the O
second O
group O
received O
intrapleural O
cisplatin O
( O
30 O
mg O
) O
therapy O
alone O
. O

Compliance O
was O
excellent O
, O
with O
7,286 O
questionnaires O
analyzed O
. O

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

Patients O
with O
untreated O
stage O
IC-IV O
ovarian O
cancer O
received O
six O
cycles O
of O
carboplatin O
area O
under O
the O
curve O
6 O
( O
AUC O
6 O
) O
3 O
weekly O
either O
with O
no O
dose O
modification O
except O
for O
toxicity O
( O
Arm O
A O
) O
or O
with O
dose O
escalations O
in O
cycles O
2-6 O
based O
on O
nadir O
neutrophil O
and O
platelet O
counts O
( O
Arm O
B O
) O
. O

To O
determine O
whether O
palliation O
of O
chest O
symptoms O
from O
a O
10 O
Gy O
single O
fraction O
( O
regimen O
1 O
) O
was O
equivalent O
to O
that O
from O
30 O
Gy O
in O
10 O
fractions O
( O
regimen O
2 O
) O
. O

A O
total O
of O
558 O
patients O
( O
mean O
age O
= O
56.9 O
years O
) O
were O
enrolled O
in O
the O
study O
between O
July O
1 O
, O
1999 O
, O
and O
June O
30 O
, O
2002 O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O

Socio-demographic O
parameters O
, O
anxiety O
and O
depression O
scales O
were O
also O
evaluated O
( O
CES-D O
, O
BDI O
and O
Spielberger O
state-trait O
questionnaires O
) O
. O

Patients O
in O
the O
IG O
and O
UCG O
were O
comparable O
with O
regard O
to O
demographics O
, O
comorbidities O
, O
cancer O
type O
and O
staging O
, O
type O
of O
resection O
, O
preoperative O
fatigue O
and O
pain O
levels O
, O
adjuvant O
therapy O
, O
and O
baseline O
walking O
distance O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
. O

IFNalpha2a O
was O
given O
daily O
subcutaneously O
, O
starting O
at O
a O
dose O
of O
3 O
million O
units O
( O
MU O
) O
. O

The O
mean O
number O
of O
hot O
flashes O
per O
day O
was O
reduced O
from O
8.7 O
( O
standard O
deviation O
[ O
SD O
] O
, O
3.9 O
) O
to O
6.2 O
( O
SD O
, O
4.2 O
) O
in O
the O
TRUE O
acupuncture O
group O
and O
from O
10.0 O
( O
SD O
, O
6.1 O
) O
to O
7.6 O
( O
SD O
, O
5.7 O
) O
in O
the O
sham O
group O
. O

All O
patients O
were O
followed O
for O
a O
median O
of O
48 O
( O
6-108 O
) O
months O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
. O

Sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0-10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O

To O
assess O
the O
safety O
and O
efficacy O
of O
thalidomide O
in O
attenuating O
weight O
loss O
in O
patients O
with O
cachexia O
secondary O
to O
advanced O
pancreatic O
cancer O
. O

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

Chronic O
gastrointestinal O
symptoms O
after O
pelvic O
radiotherapy O
are O
common O
, O
multifactorial O
in O
cause O
, O
and O
affect O
patients O
' O
quality O
of O
life O
. O

Using O
a O
computer-generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1:1:1 O
";" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
IBDQ-B O
score O
< O
60 O
vs O
60-70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self-help O
booklet O
) O
, O
gastroenterologist-led O
algorithm-based O
treatment O
, O
or O
nurse-led O
algorithm-based O
treatment O
. O

We O
conducted O
a O
pragmatic O
, O
randomized O
controlled O
trial O
comparing O
acupuncture O
with O
enhanced O
usual O
care O
. O

One O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained-release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0.6 O
mg O
( O
25 O
microg/h O
) O
of O
transdermal O
fentanyl O
. O

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

Pre- O
and O
post-assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

Patients O
completed O
a O
comprehensive O
battery O
of O
QOL O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O

The O
median O
duration O
of O
therapy O
was O
39 O
weeks O
for O
bicalutamide-treated O
patients O
and O
42 O
weeks O
for O
castrated O
patients O
";" O
treatment O
failure O
occurred O
in O
53 O
% O
and O
42 O
% O
and O
disease O
progression O
in O
43 O
% O
and O
33 O
% O
, O
respectively O
. O

Patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O

Women O
with O
platinum-pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg/m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
RT O
. O

To O
compare O
in O
a O
phase O
III O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
CVP O
) O
in O
recurrent O
, O
low-grade O
, O
non-Hodgkin O
's O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O

National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
CO.17 O
demonstrated O
the O
antiepidermal O
growth O
factor O
receptor O
( O
anti-EGFR O
) O
monoclonal O
antibody O
cetuximab O
improves O
overall O
and O
progression-free O
survival O
in O
patients O
with O
advanced O
, O
chemotherapy-refractory O
colorectal O
cancer O
( O
CRC O
) O
, O
particularly O
in O
patients O
with O
wild-type O
KRAS O
tumors O
. O

To O
determine O
whether O
weekly O
epoetin O
alfa O
could O
improve O
hemoglobin O
( O
HgB O
) O
levels O
, O
reduce O
RBC O
transfusions O
, O
and O
improve O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
advanced O
cancer O
and O
with O
anemia O
after O
receiving O
myelosuppressive O
chemotherapy O
. O

We O
aimed O
to O
test O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
clinical O
and O
cost O
effectiveness O
of O
a O
rehabilitation O
intervention O
for O
patients O
with O
advanced O
, O
recurrent O
cancer O
. O

Three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O

Postoperatively O
, O
body O
mass O
index O
( O
BMI O
) O
and O
nutritional O
conditions O
were O
measured O
serially O
, O
and O
QOL O
and O
postoperative O
squalor O
scores O
were O
evaluated O
at O
3 O
, O
12 O
, O
and O
60 O
months O
and O
compared O
between O
the O
2 O
groups O
. O

Baseline O
HRQOL O
scores O
did O
not O
differ O
between O
groups O
. O

Ten O
common O
symptoms O
were O
assessed O
by O
self-report O
questionnaire O
administered O
to O
1,614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double-blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor-positive O
breast O
cancer O
. O

Meta-analysis O
of O
published O
studies O
was O
also O
conducted O
. O

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

The O
2 O
+ O
2.5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O

There O
were O
no O
differences O
in O
the O
two O
treatment O
groups O
at O
baseline O
. O

A O
measure O
of O
3.7 O
GBq O
of O
radioiodine O
was O
given O
to O
both O
groups O
. O

Adult O
patients O
with O
anaemia O
( O
Hb O
< O
11 O
g/dL O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30,000 O
IU O
or O
20,000 O
IU O
once O
weekly O
for O
12 O
weeks O
. O

Monthly O
fatigue O
assessments O
were O
completed O
between O
T2 O
and O
T3 O
. O

We O
studied O
the O
effect O
of O
a O
new O
bisphosphonate O
, O
zoledronic O
acid O
, O
which O
blocks O
bone O
destruction O
, O
on O
skeletal O
complications O
in O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

Patients O
undergoing O
UAE O
were O
randomly O
assigned O
to O
receive O
TAGMs O
or O
PVA O
. O

The O
second O
International O
Society O
of O
Paediatric O
Oncology O
( O
SIOP O
) O
study O
for O
rhabdomyosarcoma O
( O
MMT84 O
) O
had O
several O
goals O
. O

Arm O
lymphoedema O
after O
lymphatic O
radiotherapy O
and O
surgery O
has O
been O
used O
in O
the O
present O
study O
as O
a O
clinical O
system O
for O
testing O
these O
drugs O
in O
a O
double-blind O
placebo-controlled O
randomised O
phase O
II O
trial O
. O

Secondary O
end O
points O
were O
progression-free O
and O
overall O
survival O
. O

Prospective O
, O
randomized O
, O
controlled O
trial O
. O

They O
may O
have O
unmet O
needs O
after O
active O
treatment O
. O

An O
integrated O
quality-survival O
product O
method O
was O
used O
to O
adjust O
any O
treatment O
effect O
on O
survival O
by O
a O
function O
of O
measured O
QoL O
, O
calculated O
over O
a O
restricted O
24-month-period O
( O
QALM-24 O
) O
. O

Baseline O
LCSS O
scores O
were O
low O
, O
indicating O
low O
symptom O
burden O
for O
patients O
without O
disease O
progression O
after O
completion O
of O
first-line O
treatment O
. O

GE/G O
median O
OS O
was O
5.6/5.1 O
months O
";" O
median O
PFS O
was O
3.4/3.0 O
months O
. O

Time-to-event O
data O
were O
analyzed O
using O
the O
Kaplan-Meier O
method O
, O
and O
a O
stratified O
log-rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O

The O
proportional O
hazards O
regression O
model O
with O
stratification O
for O
treatment O
, O
and O
the O
logistic O
regression O
model O
adjusting O
for O
treatment O
arm O
were O
used O
for O
univariate O
and O
multivariate O
analyses O
of O
survival O
and O
response O
to O
treatment O
, O
respectively O
. O

Data O
from O
these O
patients O
were O
used O
for O
confirmative O
purposes O
. O

Quality O
of O
life O
was O
measured O
by O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
for O
Palliative O
Care O
( O
score O
range O
, O
0-184 O
) O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
EUC O
";" O
n O
= O
230 O
) O
. O

Follow-up O
assessments O
were O
at O
2 O
, O
4 O
and O
8 O
weeks O
postdischarge O
. O

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

The O
EORTC O
24971/TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression-free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5-fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

To O
evaluate O
the O
incidence O
and O
temporal O
resolution O
of O
dysuria O
after O
permanent O
prostate O
brachytherapy O
, O
and O
to O
identify O
predictors O
of O
brachytherapy-related O
dysuria O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

The O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
as O
the O
cost O
per O
quality-adjusted O
life O
year O
( O
QALY O
) O
gained O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

We O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
lay-administered O
tailored O
education O
and O
coaching O
( O
TEC O
) O
intervention O
( O
aimed O
at O
reducing O
pain O
misconceptions O
and O
enhancing O
self-efficacy O
for O
communicating O
with O
physicians O
) O
on O
cancer O
pain O
severity O
, O
pain-related O
impairment O
, O
and O
quality O
of O
life O
. O

A O
response O
analysis O
compared O
the O
proportion O
of O
patients O
who O
demonstrated O
an O
important O
change O
in O
QOL O
. O

We O
examined O
intrusive O
thoughts O
about O
cancer O
at O
the O
baseline O
assessment O
as O
a O
predictor O
of O
fatigue O
, O
sleep O
problems O
, O
pain O
, O
breast O
cancer-specific O
symptoms O
, O
depressive O
symptoms O
, O
negative O
affect O
, O
and O
quality O
of O
life O
using O
growth O
curve O
modeling O
, O
controlling O
for O
study O
condition O
and O
other O
covariates O
. O

A O
randomized O
phase O
III O
trial O
was O
conducted O
to O
determine O
whether O
combination O
therapy O
with O
13-cis-retinoic O
acid O
( O
13-CRA O
) O
plus O
interferon O
alfa-2a O
( O
IFNalpha2a O
) O
is O
superior O
to O
IFNalpha2a O
alone O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O

An O
EGP O
does O
not O
unequivocally O
affect O
positive O
HRQoL O
outcomes O
. O

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

However O
, O
intervention B-Premise
patients I-Premise
had I-Premise
significantly I-Premise
better I-Premise
scores I-Premise
at I-Premise
months I-Premise
3 I-Premise
and I-Premise
6 I-Premise
( I-Premise
median I-Premise
3-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
5-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
5 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
";" I-Premise
median I-Premise
6-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
6-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
6 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.009 I-Premise
] I-Premise
) I-Premise
. I-Premise

After B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
HQL I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
( I-Premise
.004 I-Premise
< I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Changes O
in O
QOL O
during O
chemotherapy O
were O
relatively O
modest O
";" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
QOL I-Premise
. I-Premise

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

Although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim

Furthermore O
, O
the B-Premise
most I-Premise
common I-Premise
toxicities I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n=9 I-Premise
, I-Premise
39.13 I-Premise
% I-Premise
) I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
, I-Premise
whereas I-Premise
those I-Premise
in I-Premise
the I-Premise
in I-Premise
Gefitinib I-Premise
group I-Premise
were I-Premise
skin I-Premise
rash I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
n=4 I-Premise
, I-Premise
17.39 I-Premise
% I-Premise
) I-Premise
. I-Premise

Experimental B-Claim
and I-Claim
early I-Claim
clinical I-Claim
investigations I-Claim
have I-Claim
demonstrated I-Claim
encouraging I-Claim
results I-Claim
for I-Claim
estramustine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
malignant I-Claim
glioma I-Claim
. O

At O
final O
analysis O
, O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
seen I-Premise
between I-Premise
ASA404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
and I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
arms I-Premise
: I-Premise
median I-Premise
OS I-Premise
was I-Premise
13.4 I-Premise
and I-Premise
12.7 I-Premise
months I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.85 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.535 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
that I-Premise
community I-Premise
treatment I-Premise
compromised I-Premise
patient I-Premise
safety I-Premise
and O
no B-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
terms I-Premise
of I-Premise
overall I-Premise
costs I-Premise
or I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Year I-Premise
. I-Premise

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

Median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Indeed O
, O
four B-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
but I-Premise
no I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
interventional I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
the B-Premise
meta-analysis I-Premise
of I-Premise
two I-Premise
additional I-Premise
studies I-Premise
involving I-Premise
935 I-Premise
patients I-Premise
showed I-Premise
a I-Premise
significant I-Premise
survival I-Premise
benefit I-Premise
in I-Premise
favor I-Premise
of I-Premise
GEM-CAP I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
0.98 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
with I-Premise
no I-Premise
intertrial I-Premise
heterogeneity I-Premise
. I-Premise

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin-alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0.126 I-Premise
] I-Premise
) I-Premise
. I-Premise

Patients B-Premise
on I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31.4 I-Premise
and I-Premise
25.3 I-Premise
weeks I-Premise
, I-Premise
12-month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18-month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O

Although B-Premise
our I-Premise
patient I-Premise
sample I-Premise
was I-Premise
small I-Premise
and I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
complete I-Premise
the I-Premise
follow-up I-Premise
survey I-Premise
were I-Premise
present I-Premise
, I-Premise
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
clinical I-Claim
difference I-Claim
between I-Claim
INT I-Claim
and I-Claim
RY I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
60 I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim

In O
light O
of O
the O
results O
obtained O
in O
the O
study O
, O
the B-Claim
extensive I-Claim
use I-Claim
of I-Claim
the I-Claim
drug I-Claim
for I-Claim
cancer I-Claim
pain I-Claim
should I-Claim
be I-Claim
questioned I-Claim
. I-Claim

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

CAF B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise

Low-frequency B-Premise
low-intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19.77 I-Premise
mL I-Premise
, I-Premise
P I-Premise
= I-Premise
0.36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13.1 I-Premise
, I-Premise
16.2 I-Premise
and I-Premise
6.4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
FACT-B+4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5.4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.015 I-Premise
) I-Premise
. I-Premise

However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost-effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long-term I-Claim
follow-up I-Claim
. I-Claim

